1
|
Healer J, Thompson JK, Mackwell KL, Browne CD, Seager BA, Ngo A, Lowes KN, Silk SE, Pulido D, King LDW, Christen JM, Noe AR, Kotraiah V, Masendycz PJ, Rajagopalan R, Lucas L, Stanford MM, Soisson L, Diggs C, Miller R, Youll S, Wycherley K, Draper SJ, Cowman AF. RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting. Front Cell Infect Microbiol 2022; 12:1049065. [PMID: 36605129 PMCID: PMC9807911 DOI: 10.3389/fcimb.2022.1049065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Accepted: 12/05/2022] [Indexed: 12/24/2022] Open
Abstract
Background RH5 is the leading vaccine candidate for the Plasmodium falciparum blood stage and has shown impact on parasite growth in the blood in a human clinical trial. RH5 binds to Ripr and CyRPA at the apical end of the invasive merozoite form, and this complex, designated RCR, is essential for entry into human erythrocytes. RH5 has advanced to human clinical trials, and the impact on parasite growth in the blood was encouraging but modest. This study assessed the potential of a protein-in-adjuvant blood stage malaria vaccine based on a combination of RH5, Ripr and CyRPA to provide improved neutralizing activity against P. falciparum in vitro. Methods Mice were immunized with the individual RCR antigens to down select the best performing adjuvant formulation and rats were immunized with the individual RCR antigens to select the correct antigen dose. A second cohort of rats were immunized with single, double and triple antigen combinations to assess immunogenicity and parasite neutralizing activity in growth inhibition assays. Results The DPX® platform was identified as the best performing formulation in potentiating P. falciparum inhibitory antibody responses to these antigens. The three antigens derived from RH5, Ripr and CyRPA proteins formulated with DPX induced highly inhibitory parasite neutralising antibodies. Notably, RH5 either as a single antigen or in combination with Ripr and/or CyRPA, induced inhibitory antibodies that outperformed CyRPA, Ripr. Conclusion An RCR combination vaccine may not induce substantially improved protective immunity as compared with RH5 as a single immunogen in a clinical setting and leaves the development pathway open for other antigens to be combined with RH5 as a next generation malaria vaccine.
Collapse
Affiliation(s)
- Julie Healer
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia,University of Melbourne, Melbourne, VIC, Australia
| | - Jennifer K. Thompson
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
| | - Karen L. Mackwell
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
| | | | - Benjamin A. Seager
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia,University of Melbourne, Melbourne, VIC, Australia
| | - Anna Ngo
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
| | - Kym N. Lowes
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia,University of Melbourne, Melbourne, VIC, Australia
| | - Sarah E. Silk
- Department of Biochemistry, University of Oxford, Oxford, United Kingdom
| | - David Pulido
- Department of Biochemistry, University of Oxford, Oxford, United Kingdom
| | - Lloyd D. W. King
- Department of Biochemistry, University of Oxford, Oxford, United Kingdom
| | | | - Amy R. Noe
- Leidos Life Sciences, Frederick, MD, United States
| | | | - Paul J. Masendycz
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
| | | | | | | | - Lorraine Soisson
- Malaria Vaccine Development Program, United States Agency for International Development (USAID), Washington, DC, United States
| | - Carter Diggs
- Malaria Vaccine Development Program, United States Agency for International Development (USAID), Washington, DC, United States
| | - Robin Miller
- Malaria Vaccine Development Program, United States Agency for International Development (USAID), Washington, DC, United States
| | - Susan Youll
- Malaria Vaccine Development Program, United States Agency for International Development (USAID), Washington, DC, United States
| | - Kaye Wycherley
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
| | - Simon J. Draper
- Department of Biochemistry, University of Oxford, Oxford, United Kingdom
| | - Alan F. Cowman
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia,University of Melbourne, Melbourne, VIC, Australia,*Correspondence: Alan F. Cowman,
| |
Collapse
|
2
|
Dirk BS, Weir G, Quinton T, Hrytsenko O, Stanford MM. Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in a HPV16 E7-expressing C3 tumour model. Sci Rep 2021; 11:4502. [PMID: 33627686 PMCID: PMC7904807 DOI: 10.1038/s41598-021-82108-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Accepted: 01/15/2021] [Indexed: 11/12/2022] Open
Abstract
DPX is a novel delivery platform that generates targeted CD8 + T cells and drives antigen-specific cytotoxic T cells into tumours. Cancer cells upregulate phosphatidylserine (PS) on the cell surface as a mechanism to induce an immunosuppressive microenvironment. Development of anti-PS targeting antibodies have highlighted the ability of a PS-blockade to enhance tumour control by T cells by releasing immunosuppression. Here, C57BL/6 mice were implanted with HPV16 E7 target-expressing C3 tumours and subjected to low dose intermittent cyclophosphamide (CPA) in combination with DPX-R9F treatment targeting an E7 antigen with and without anti-PS and/or anti-PD-1 targeting antibodies. Immune responses were assessed via IFN-γ ELISPOT assay and the tumour microenvironment was further analyzed using RT-qPCR. We show that the combination of DPX-R9F and PS-targeting antibodies with and without anti-PD-1 demonstrated increased efficacy compared to untreated controls. All treatments containing DPX-R9F led to T cell activation as assessed by IFN-γ ELISPOT. Furthermore, DPX-R9F/anti-PS treatment significantly elevated cytotoxic T cells, macrophages and dendritic cells based on RT-qPCR analysis. Overall, our data indicates that anti-tumour responses are driven through a variety of immune cells within this model and highlights the need to investigate combination therapies which increase tumour immune infiltration, such as anti-phosphotidylserine.
Collapse
Affiliation(s)
| | | | | | | | - Marianne M Stanford
- IMV Inc, Dartmouth, NS, Canada.
- Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.
| |
Collapse
|
3
|
Woo Y, Warner SG, Geha R, Stanford MM, Decarolis P, Rahman MM, Singer S, McFadden G, Fong Y. The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase. Clin Med Insights Oncol 2021; 15:1179554921993069. [PMID: 33633477 PMCID: PMC7887694 DOI: 10.1177/1179554921993069] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Accepted: 01/15/2021] [Indexed: 01/17/2023] Open
Abstract
BACKGROUND Myxoma virus (MYXV) is an oncolytic poxvirus that lacks the gene for 1 of the subunits of ribonucleotide reductase (RR), a crucial DNA synthesis and repair enzyme. The overexpression of RR has been implicated in the invasiveness of several cancers, including soft tissue sarcomas (STS). The purpose of the study was to investigate the oncolytic efficacy of MYXV in STS with different levels of RR expression. METHODS The oncolytic effect of recombinant MYXV was evaluated in 4 human STS cell lines, LS141 (a dedifferentiated liposarcoma), DDLS8817 (a dedifferentiated liposarcoma), RDD2213 (recurrent dedifferentiated liposarcoma), and HSSYII (a synovial sarcoma) using infectivity and cytotoxicity assays. Following the overexpression of RRM2 by cDNA transfection and silencing of RRM2 by siRRM2 in these STS cell lines, the RRM2 expression levels were analyzed by Western blot. RESULTS We observed a direct correlation between viral oncolysis and RRM2 mRNA levels (R = 0.96) in STS. Higher RRM2 expression was associated with a more robust cell kill. Silencing the RRM2 gene led to significantly greater cell survival (80%) compared with the control group (P = .003), whereas overexpression of the RRM2 increased viral oncolysis by 33% (P < .001). CONCLUSIONS Our results show that the oncolytic effects of MYXV correlate directly with RR expression levels and are enhanced in STS cell lines with naturally occurring or artificially induced high expression levels of RR. Myxoma virus holds promise in the treatment of advanced soft tissue cancer, especially in tumors overexpressing RR.
Collapse
Affiliation(s)
- Yanghee Woo
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA
| | - Susanne G Warner
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA
| | - Rula Geha
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Marianne M Stanford
- Department of Microbiology & Immunology, Dalhousie University, Halifax, NS, Canada
| | - Penelope Decarolis
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Department of Molecular Pharmacology, Albert Einstein College of Medicine, New York, NY, USA
| | - Masmudur M Rahman
- Department of Molecular Genetics & Microbiology, University of Florida, Gainesville, FL, USA
- Center for Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA
| | - Samuel Singer
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Grant McFadden
- Department of Molecular Genetics & Microbiology, University of Florida, Gainesville, FL, USA
- Center for Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA
| | - Yuman Fong
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA
| |
Collapse
|
4
|
Vila-Leahey A, MacKay A, Portales-Cervantes L, Weir GM, Merkx-Jacques A, Stanford MM. Generation of highly activated, antigen-specific tumor-infiltrating CD8 + T cells induced by a novel T cell-targeted immunotherapy. Oncoimmunology 2020; 9:1782574. [PMID: 32923145 PMCID: PMC7458631 DOI: 10.1080/2162402x.2020.1782574] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The induction of tumor-targeted, cytotoxic T lymphocytes has been recognized as a key component to successful immunotherapy. DPX-based treatment was previously shown to effectively recruit activated CD8+ T cells to the tumor. Herein, we analyze the unique phenotype of the CD8+ T cells recruited into the tumor in response to DPX-based therapy, and how combination with checkpoint inhibitors impacts T cell response. C3-tumor-bearing mice were treated with cyclophosphamide (CPA) for seven continuous days every other week, followed by DPX treatment along with anti-CTLA-4 and/or anti-PD-1. Efficacy, immunogenicity, and CD8+ T cells tumor infiltration were assessed. The expression of various markers, including checkpoint markers, peptide specificity, and proliferation and activation markers, was determined by flow cytometry. tSNE analysis of the flow data revealed a resident phenotype of CD8+ T cells (PD-1+TIM-3+CTLA-4+) within untreated tumors, whereas DPX/CPA treatment induced recruitment of a novel population of CD8+ T cells (PD-1+TIM-3+CTLA-4−) within tumors. Combination of anti-CTLA-4 (ipilimumab) with DPX/CPA versus DPX/CPA alone significantly increased survival and inhibition of tumor growth, without changing overall systemic immunogenicity. Addition of checkpoint inhibitors did not significantly change the phenotype of the newly recruited cells induced by DPX/CPA. Yet, anti-CTLA-4 treatment in combination with DPX/CPA enhanced a non-antigen specific response within the tumor. Finally, the tumor-recruited CD8+ T cells induced by DPX/CPA were highly activated, antigen-specific, and proliferative, while resident phenotype CD8+ T cells, seemingly initially exhausted, were reactivated with combination treatment. This study supports the potential of combining DPX/CPA with ipilimumab to further enhance survival clinically.
Collapse
Affiliation(s)
| | - Alecia MacKay
- Research and Development, IMV Inc, Dartmouth, NS, Canada
| | | | | | | | - Marianne M Stanford
- Research and Development, IMV Inc, Dartmouth, NS, Canada.,Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada
| |
Collapse
|
5
|
Torrey HL, Kaliaperumal V, Bramhecha Y, Weir GM, Falsey AR, Walsh EE, Langley JM, Schepens B, Saelens X, Stanford MM. Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein. Hum Vaccin Immunother 2020; 16:2007-2017. [PMID: 32530723 PMCID: PMC7553696 DOI: 10.1080/21645515.2020.1756671] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
The small hydrophobic (SH) glycoprotein of human respiratory syncytial virus (RSV) is a transmembrane protein that is poorly accessible by antibodies on the virion but has an ectodomain (SHe) that is accessible and expressed on infected cells. The SHe from RSV strain A has been formulated in DPX, a unique delivery platform containing an adjuvant, and is being evaluated as an RSV vaccine candidate. The proposed mechanism of protection is the immune-mediated clearance of infected cells rather than neutralization of the virion. Our phase I clinical trial data clearly showed that vaccination resulted in robust antibody responses, but it was unclear if these immune responses have any correlation to immune responses to natural infection with RSV. Therefore, we embarked on this study to examine these immune responses in older adults with confirmed RSV infection. We compared vaccine-induced (DPX-RSV(A)) immune responses from participants in a Phase 1 clinical trial to paired acute and convalescent titers from older adults with symptomatic laboratory-confirmed RSV infection. Serum samples were tested for anti-SHe IgG titers and the isotypes determined. T cell responses were evaluated by IFN-γ ELISPOT. Anti-SHe titers were detected in 8 of 42 (19%) in the acute phase and 16 of 42 (38%) of convalescent serum samples. IgG1, IgG3, and IgA were the prevalent isotypes generated by both vaccination and infection. Antigen-specific T cell responses were detected in 9 of 16 (56%) of vaccinated participants. Depletion of CD4+ but not CD8+ T cells abrogated the IFN-γ ELISPOT response supporting the involvement of CD4+ T cells in the immune response to vaccination. The data showed that an immune response like that induced by DPX-RSV(A) could be seen in a subset of participants with confirmed RSV infection. These findings show that older adults with clinically significant infection as well as vaccinated adults generate a humoral response to SHe. The induction of both SHe-specific antibody and cellular responses support further clinical development of the DPX-RSV(A) vaccine.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Joanne M Langley
- Canadian Center for Vaccinology (IWK Health Centre and Nova Scotia Health Authority and Dalhousie University) , Halifax, NS, Canada.,Dalhousie University , Halifax, NS, Canada
| | - Bert Schepens
- VIB-UGent Center for Medical Biotechnology , Ghent, Belgium.,Ghent University , Ghent, Belgium
| | - Xavier Saelens
- VIB-UGent Center for Medical Biotechnology , Ghent, Belgium.,Ghent University , Ghent, Belgium
| | - Marianne M Stanford
- IMV Inc ., Dartmouth, NS, Canada.,Dalhousie University , Halifax, NS, Canada
| |
Collapse
|
6
|
Kotraiah V, Phares TW, Browne CD, Pannucci J, Mansour M, Noe AR, Tucker KD, Christen JM, Reed C, MacKay A, Weir GM, Rajagopalan R, Stanford MM, Chung CS, Ayala A, Huang J, Tsuji M, Gutierrez GM. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics. Front Immunol 2020; 11:264. [PMID: 32210956 PMCID: PMC7068811 DOI: 10.3389/fimmu.2020.00264] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2019] [Accepted: 01/31/2020] [Indexed: 12/31/2022] Open
Abstract
Many pathogens use the same immune evasion mechanisms as cancer cells. Patients with chronic infections have elevated levels of checkpoint receptors (e.g., programed cell death 1, PD1) on T cells. Monoclonal antibody (mAb)-based inhibitors to checkpoint receptors have also been shown to enhance T-cell responses in models of chronic infection. Therefore, inhibitors have the potential to act as a vaccine “adjuvant” by facilitating the expansion of vaccine antigen-specific T-cell repertoires. Here, we report the discovery and characterization of a peptide-based class of PD1 checkpoint inhibitors, which have a potent adaptive immunity adjuvant capability for vaccines against infectious diseases. Briefly, after identifying peptides that bind to the recombinant human PD1, we screened for in vitro efficacy in reporter assays and human peripheral blood mononuclear cells (PBMC) readouts. We first found the baseline in vivo performance of the peptides in a standard mouse oncology model that demonstrated equivalent efficacy compared to mAbs against the PD1 checkpoint. Subsequently, two strategies were used to demonstrate the utility of our peptides in infectious disease indications: (1) as a therapeutic in a bacteria-induced lethal sepsis model in which our peptides were found to increase survival with enhanced bacterial clearance and increased macrophage function; and (2) as an adjuvant in combination with a prophylactic malaria vaccine in which our peptides increased T-cell immunogenicity and the protective efficacy of the vaccine. Therefore, our peptides are promising as both a therapeutic agent and a vaccine adjuvant for infectious disease with a potentially safer and more cost-effective target product profile compared to mAbs. These findings are essential for deploying a new immunomodulatory regimen in infectious disease primary and clinical care settings.
Collapse
Affiliation(s)
- Vinayaka Kotraiah
- Explorations in Global Health (ExGloH), Leidos Inc., Frederick, MD, United States
| | - Timothy W Phares
- Explorations in Global Health (ExGloH), Leidos Inc., Frederick, MD, United States
| | | | - James Pannucci
- Explorations in Global Health (ExGloH), Leidos Inc., Frederick, MD, United States
| | - Marc Mansour
- MM Scientific Consultants, Inc., Halifax, NS, Canada
| | - Amy R Noe
- Leidos Life Sciences, Leidos Inc., Frederick, MD, United States
| | | | | | - Charles Reed
- Inovio Pharmaceuticals, Plymouth Meeting, PA, United States
| | | | | | | | | | | | - Alfred Ayala
- Lifespan-Rhode Island Hospital, Providence, RI, United States
| | - Jing Huang
- The Aaron Diamond AIDS Research Center, New York, NY, United States
| | - Moriya Tsuji
- The Aaron Diamond AIDS Research Center, New York, NY, United States
| | - Gabriel M Gutierrez
- Explorations in Global Health (ExGloH), Leidos Inc., Frederick, MD, United States
| |
Collapse
|
7
|
Weir GM, MacDonald LD, Rajagopalan R, Sivko GS, Valderas MW, Rayner J, Berger BJ, Sammatur L, Stanford MM. Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillus anthracis spore inhalation challenge. NPJ Vaccines 2019; 4:6. [PMID: 30774997 PMCID: PMC6368554 DOI: 10.1038/s41541-019-0102-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2018] [Accepted: 01/16/2019] [Indexed: 01/15/2023] Open
Abstract
Anthrax is a serious biological threat caused by pulmonary exposure to aerosolized spores of Bacillus anthracis. Biothrax® (anthrax vaccine adsorbed (AVA)) is the only Food and Drug Administration-licensed vaccine and requires five administrations over 12 months with annual boosting to maintain pre-exposure prophylaxis. Here we report the evaluation of a single intramuscular injection of recombinant B. anthracis-protective antigen (rPA) formulated in the DPX delivery platform. Immune responses were compared to an alum-based formulation in mice and rabbits. Serological analysis of anti-rPA immunoglobulin G and toxin neutralization activity demonstrated higher responses induced by DPX-rPA when compared to rPA in alum. DPX-rPA was compared to AVA in rabbits and non-human primates (NHPs). In both species, DPX-rPA generated responses after a single immunization, whereas AVA required two immunizations. In rabbits, single injection of DPX-rPA or two injections of AVA conferred 100% protection from anthrax challenge. In NHPs, single-dose DPX-rPA was 100% protective against challenge, whereas one animal in the two-dose AVA group and all saline administered animals succumbed to infection. DPX-rPA was minimally reactogenic in all species tested. These data indicate that DPX-rPA may offer improvement over AVA by reducing the doses needed for protective immune responses and is a promising candidate as a new-generation anthrax vaccine. A lipid-based anthrax vaccine formulation offers immunity from the first injection. Bacillus anthracis is a lethal pathogen at high risk for use in biological warfare. The only FDA-licensed vaccine for anthrax, AVA, requires multiple doses over six months followed by regular boosters, indicating a need for rapidly immunizing vaccines. Genevieve Weir and Lisa MacDonald, from IMV Inc., with Canadian and US collaborators, here describe a prophylactic consisting of B. anthracis antigens suspended in a lipid-in-oil formulation. Their candidate, DPX-rPA, generated antigen-specific antibodies in rabbits and monkeys after one dose, compared to two for AVA. DPX-rPA also protected both species from B. anthracis spores after one dose. The results indicate that single-dose DPX-rPA is equally protective as two doses of AVA and could serve as pre-exposure and post-exposure prophylaxis. Future studies may confirm its potential as a vaccine for humans.
Collapse
Affiliation(s)
- Genevieve M Weir
- IMV Inc., 130 Eileen Stubbs Avenue, Suite 19, Dartmouth, NS B3B 2C4 Canada
| | - Lisa D MacDonald
- IMV Inc., 130 Eileen Stubbs Avenue, Suite 19, Dartmouth, NS B3B 2C4 Canada
| | | | - Gloria S Sivko
- 2Battelle, 1425 Plain City Georgesville Road, West Jefferson, OH 43162 USA
| | | | - Jonathan Rayner
- 3Southern Research, 2000 9th Avenue S, Birmingham, AL 35205 USA
| | - Bradley J Berger
- 4Suffield Research Centre, Defence Research and Development Canada, Medicine Hat, AB T1A 8K6 Canada
| | - Leeladhar Sammatur
- IMV Inc., 130 Eileen Stubbs Avenue, Suite 19, Dartmouth, NS B3B 2C4 Canada
| | - Marianne M Stanford
- IMV Inc., 130 Eileen Stubbs Avenue, Suite 19, Dartmouth, NS B3B 2C4 Canada.,5Department of Microbiology and Immunology, Dalhousie University, 5850 College Street, Room 7-C, PO BOX 15000, Halifax, NS B3H 4R2 Canada
| |
Collapse
|
8
|
Langley JM, MacDonald LD, Weir GM, MacKinnon-Cameron D, Ye L, McNeil S, Schepens B, Saelens X, Stanford MM, Halperin SA. A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study. J Infect Dis 2018; 218:378-387. [PMID: 29617814 PMCID: PMC6049039 DOI: 10.1093/infdis/jiy177] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2017] [Accepted: 03/28/2018] [Indexed: 12/22/2022] Open
Abstract
Background Respiratory syncytial virus infection can cause lower respiratory tract infection in older adults comparable to influenza, but no vaccines are available. Methods This was a randomized, observer-blinded, first-in-humans study of a novel synthetic RSV antigen based on the ectodomain of the small hydrophobic glycoprotein (SHe) of RSV subgroup A, formulated with either the lipid and oil-based vaccine platform DepoVax (DPX-RSV[A]) or alum (RSV[A]-Alum), in healthy, 50-64-year-old individuals. Two dose levels (10 or 25 µg) of SHe with each formulation were compared to placebo. A booster dose was administered on day 56. Results There was no indication that the vaccine was unsafe. Mild pain, drowsiness, and muscles aches were the most common solicited adverse events (AEs), and the frequencies of the AEs did not increase after dose 2. Robust anti-SHe-specific immune responses were demonstrated in the DPX-RSV(A) 10-μg and 25-μg groups (geometric mean titer, approximately 10-fold and 100-fold greater than that of placebo at days 56 and 236, respectively), and responses were sustained in the DPX-RSV(A) 25-μg group at day 421. Responses to the RSV(A)-Alum vaccines were very low. Conclusions A novel antigen from the SH protein of RSV, formulated in a lipid and oil-based vaccine platform, was highly immunogenic, with sustained antigen-specific antibody responses, and had an acceptable safety profile.
Collapse
Affiliation(s)
- Joanne M Langley
- Canadian Center for Vaccinology (Dalhousie University, IWK Health Centre, and the Nova Scotia Health Authority)
- Department of Pediatrics, Dalhousie University, Halifax, Canada
- Department of Community Health and Epidemiology, Dalhousie University, Halifax, Canada
| | | | | | - Donna MacKinnon-Cameron
- Canadian Center for Vaccinology (Dalhousie University, IWK Health Centre, and the Nova Scotia Health Authority)
| | - Lingyun Ye
- Canadian Center for Vaccinology (Dalhousie University, IWK Health Centre, and the Nova Scotia Health Authority)
| | - Shelly McNeil
- Canadian Center for Vaccinology (Dalhousie University, IWK Health Centre, and the Nova Scotia Health Authority)
- Department of Pediatrics, Dalhousie University, Halifax, Canada
- Department of Community Health and Epidemiology, Dalhousie University, Halifax, Canada
- Department of Medicine, Dalhousie University, Halifax, Canada
| | - Bert Schepens
- VIB-UGent Center for Medical Biotechnology, VIB, Ghent University, Ghent, Belgium
- Department for Biomedical Molecular Biology, Ghent University, Ghent, Belgium
| | - Xavier Saelens
- VIB-UGent Center for Medical Biotechnology, VIB, Ghent University, Ghent, Belgium
- Department for Biomedical Molecular Biology, Ghent University, Ghent, Belgium
| | - Marianne M Stanford
- Canadian Center for Vaccinology (Dalhousie University, IWK Health Centre, and the Nova Scotia Health Authority)
- Department of Microbiology and Immunology, Dalhousie University, Halifax, Canada
- Immunovaccine, Halifax, Canada
| | - Scott A Halperin
- Canadian Center for Vaccinology (Dalhousie University, IWK Health Centre, and the Nova Scotia Health Authority)
- Department of Pediatrics, Dalhousie University, Halifax, Canada
- Department of Microbiology and Immunology, Dalhousie University, Halifax, Canada
| |
Collapse
|
9
|
Hrytsenko O, Weir GM, Stanford MM. Combination of a DepoVax™ peptide vaccine with a lentivector vaccine induces strong antigen-specific immune responses and provides effective tumor control in murine models. The Journal of Immunology 2018. [DOI: 10.4049/jimmunol.200.supp.181.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Many strategies are being investigated to induce and sustain anti-tumor immune responses through vaccination. Viral vectors have been used to induce robust cellular immune responses, however due to immune responses against the vector they loose potency with boosting vaccinations. In this study, we investigated a heterologous prime boost strategy that combines lentivirus and peptide vaccination to induce robust anti-tumour immune responses in a preclinical model.
DepoVax™ is a water-free vaccine formulation that facilities strong and sustained immune responses to peptide antigens. We showed that while homologous immunizations with DepoVax peptide vaccine containing HPV16 E749–57 T cell peptide antigen (DPX-FP) elicit potent antigen-specific responses, heterologous prime-boost immunizations with DPX-FP and lentivector vaccine expressing HPV16 E7 protein could further enhance systemic immune responses detected by IFN-γ ELISPOT. The synergy between two vaccines is influenced by the order of vaccine administration, dose, and delivery route. Using an HPV-expressing murine tumor model (C3), we found that heterologous priming with the DPX-FP vaccine and boosting with E7 lentivector vaccine enhanced tumor control and increased survival rates as compared to the treatments with either vaccine alone. RT-qPCR profiling demonstrated that the vaccine-draining lymph node cells of mice primed with DPX-FP and boosted with E7 lentivector vaccine had an altered immune gene signature with an increased expression of cytotoxic T lymphocyte markers (Gzmb and Tbx21). Taken together our results support a rationale for combining DepoVax based therapy with lentivector vaccines in future clinical trials.
Collapse
|
10
|
Brewer KD, Weir GM, Dude I, Davis C, Parsons C, Penwell A, Rajagopalan R, Sammatur L, Bowen CV, Stanford MM. Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control. J Biomed Sci 2018; 25:7. [PMID: 29374458 PMCID: PMC5787234 DOI: 10.1186/s12929-018-0413-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2017] [Accepted: 01/18/2018] [Indexed: 01/04/2023] Open
Abstract
Background Oil emulsions are commonly used as vaccine delivery platforms to facilitate slow release of antigen by forming a depot at the injection site. Antigen is trapped in the aqueous phase and as the emulsion degrades in vivo the antigen is passively released. DepoVax™ is a unique oil based delivery system that directly suspends the vaccine components in the oil diluent that forces immune cells to actively take up components from the formulation in the absence of passive release. The aim of this study was to use magnetic resonance imaging (MRI) with additional biological markers to evaluate and understand differences in clearance between several different delivery systems used in peptide-based cancer vaccines. Methods C57BL/6 mice were implanted with a cervical cancer model and vaccinated 5 days post-implant with either DepoVax (DPX), a water-in-oil emulsion (w/o), a squalene oil-in-water emulsion (squal o/w) or a saponin/liposome emulsion (sap/lip) containing iron oxide-labeled targeted antigen. MRI was then used to monitor antigen clearance, the site of injection, tumour and inguinal lymph node volumes and other gross anatomical changes. HLA-A2 transgenic mice were also vaccinated to evaluate immune responses of human directed peptides. Results We demonstrated differences in antigen clearance between DPX and w/o both in regard to how quickly the antigen was cleared and the pattern in which it was cleared. We also found differences in lymph node responses between DPX and both squal o/w and sap/lip. Conclusions These studies underline the unique mechanism of action of this clinical stage vaccine delivery system. Electronic supplementary material The online version of this article (10.1186/s12929-018-0413-9) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Kimberly D Brewer
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada.,Department of Diagnostic Radiology, Dalhousie University, Halifax, NS, Canada.,Department of Physics and Atmospheric Science, Dalhousie University, Halifax, NS, Canada.,Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.,School of Biomedical Engineering, Dalhousie University, Halifax, NS, Canada
| | | | - Iulia Dude
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada
| | - Christa Davis
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada
| | - Cathryn Parsons
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada
| | | | | | | | - Chris V Bowen
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada.,Department of Diagnostic Radiology, Dalhousie University, Halifax, NS, Canada.,Department of Physics and Atmospheric Science, Dalhousie University, Halifax, NS, Canada.,School of Biomedical Engineering, Dalhousie University, Halifax, NS, Canada
| | - Marianne M Stanford
- Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.,Immunovaccine Inc., Halifax, NS, Canada
| |
Collapse
|
11
|
Brewer KD, DeBay DR, Dude I, Davis C, Lake K, Parsons C, Rajagopalan R, Weir G, Stanford MM, Mansour M, Bowen CV. Using lymph node swelling as a potential biomarker for successful vaccination. Oncotarget 2018; 7:35655-35669. [PMID: 27232944 PMCID: PMC5094952 DOI: 10.18632/oncotarget.9580] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Accepted: 05/12/2016] [Indexed: 12/14/2022] Open
Abstract
There is currently a lack of biomarkers to help properly assess novel immunotherapies at both the preclinical and clinical stages of development. Recent work done by our group indicated significant volume changes in the vaccine draining right lymph node (RLN) volumes of mice that had been vaccinated with DepoVaxTM, a lipid-based vaccine platform that was developed to enhance the potency of peptide-based vaccines. These changes in lymph node (LN) volume were unique to vaccinated mice.To better assess the potential of volumetric LN markers for multiple vaccination platforms, we evaluated 100 tumor bearing mice and assessed their response to vaccination with either a DepoVax based vaccine (DPX) or a water-in-oil emulsion (w/o), and compared them to untreated controls. MRI was used to longitudinally monitor LN and tumor volumes weekly over 4 weeks. We then evaluated changes in LN volumes occurring in response to therapy as a potential predictive biomarker for treatment success.We found that for both vaccine types, DPX and w/o, the %RLN volumetric increase over baseline and the ratio of RLN/LLN were strong predictors of successful tumor suppression (LLN is left inguinal LN). The area under the curve (AUC) was greatest, between 0.75-0.85, two (%RLN) or three (RLN/LLN) weeks post-vaccination. For optimized critical thresholds we found these biomarkers consistently had sensitivity >90% and specificity >70% indicating strong prognostic potential. Vaccination with DepoVax had a more pronounced effect on draining lymph nodes than w/o emulsion vaccines, which correlated with a higher anti-tumor activity in DPX-treated mice.
Collapse
Affiliation(s)
- Kimberly D Brewer
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada.,Department of Radiology, Dalhousie University, Halifax, NS, Canada.,Department of Physics, Dalhousie University, Halifax, NS, Canada
| | - Drew R DeBay
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada
| | - Iulia Dude
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada
| | - Christa Davis
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada
| | - Kerry Lake
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada
| | - Cathryn Parsons
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada
| | | | | | - Marianne M Stanford
- Immunovaccine Inc., Halifax, NS, Canada.,Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada
| | | | - Chris V Bowen
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada.,Department of Radiology, Dalhousie University, Halifax, NS, Canada.,Department of Physics, Dalhousie University, Halifax, NS, Canada.,School of Biomedical Engineering, Dalhousie University, Halifax, NS, Canada
| |
Collapse
|
12
|
Tremblay ML, Davis C, Bowen CV, Stanley O, Parsons C, Weir G, Karkada M, Stanford MM, Brewer KD. Using MRI cell tracking to monitor immune cell recruitment in response to a peptide-based cancer vaccine. Magn Reson Med 2017; 80:304-316. [PMID: 29193231 DOI: 10.1002/mrm.27018] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Revised: 10/26/2017] [Accepted: 10/28/2017] [Indexed: 12/18/2022]
Abstract
PURPOSE MRI cell tracking can be used to monitor immune cells involved in the immunotherapy response, providing insight into the mechanism of action, temporal progression of tumor growth, and individual potency of therapies. To evaluate whether MRI could be used to track immune cell populations in response to immunotherapy, CD8+ cytotoxic T cells, CD4+ CD25+ FoxP3+ regulatory T cells, and myeloid-derived suppressor cells were labeled with superparamagnetic iron oxide particles. METHODS Superparamagnetic iron oxide-labeled cells were injected into mice (one cell type/mouse) implanted with a human papillomavirus-based cervical cancer model. Half of these mice were also vaccinated with DepoVaxTM (ImmunoVaccine, Inc., Halifax, Nova Scotia, Canada), a lipid-based vaccine platform that was developed to enhance the potency of peptide-based vaccines. RESULTS MRI visualization of CD8+ cytotoxic T cells, regulatory T cells, and myeloid-derived suppressor cells was apparent 24 h post-injection, with hypointensities due to iron-labeled cells clearing approximately 72 h post-injection. Vaccination resulted in increased recruitment of CD8+ cytotoxic T cells, and decreased recruitment of myeloid-derived suppressor cells and regulatory T cells to the tumor. We also found that myeloid-derived suppressor cell and regulatory T cell recruitment were positively correlated with final tumor volume. CONCLUSION This type of analysis can be used to noninvasively study changes in immune cell recruitment in individual mice over time, potentially allowing improved application and combination of immunotherapies. Magn Reson Med 80:304-316, 2018. © 2017 International Society for Magnetic Resonance in Medicine.
Collapse
Affiliation(s)
| | - Christa Davis
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, Nova Scotia, Canada
| | - Chris V Bowen
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, Nova Scotia, Canada.,Department of Diagnostic Radiology, Dalhousie University, Halifax, Nova Scotia, Canada.,Department of Physics and Atmospheric Science, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Olivia Stanley
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, Nova Scotia, Canada
| | - Cathryn Parsons
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, Nova Scotia, Canada
| | | | - Mohan Karkada
- Wyss Institute at Harvard Medical School, Boston, Massachusetts, USA
| | - Marianne M Stanford
- Immunovaccine Inc., Halifax, Nova Scotia, Canada.,Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Kimberly D Brewer
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, Nova Scotia, Canada.,Department of Diagnostic Radiology, Dalhousie University, Halifax, Nova Scotia, Canada.,Department of Physics and Atmospheric Science, Dalhousie University, Halifax, Nova Scotia, Canada.,School of Biomedical Engineering, Dalhousie University, Halifax, Nova Scotia, Canada.,Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada
| |
Collapse
|
13
|
MacDonald LD, MacKay A, Kaliaperumal V, Weir G, Penwell A, Rajagopalan R, Langley JM, Halperin S, Mansour M, Stanford MM. Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform. Hum Vaccin Immunother 2017; 14:59-66. [PMID: 28933663 PMCID: PMC5791585 DOI: 10.1080/21645515.2017.1375637] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Abstract
Peptide antigens are combined with an adjuvant in order to increase immunogenicity in vivo. The immunogenicity and safety of a RSV vaccine formulated in a novel oil-based platform, DepoVax™ (DPX), was compared to an alum formulation. A peptide B cell epitope derived from RSV small hydrophobic ectodomain (SHe) served as the antigen. Both vaccines induced SHe-specific antibodies after immunization of mice. A single dose of the DPX-based formulation resulted in anti-SHe titres for up to 20 weeks. Boosting with Alum-SHe, but not with DPX-SHe, led to unexpected clinical signs such as decreased activity, cyanosis and drop in body temperature in mice but not in rabbits. The severity of adverse reactions correlated with magnitude of SHe-specific IgG immune responses and decreased complement component 3 plasma levels, indicating a type III hypersensitivity reaction. By RP-HPLC analysis, we found that only 8-20% of the antigen was found to be adsorbed to alum in vitro, indicating that this antigen is likely released systemically upon injection in vivo. Clinical signs were not observed in rabbits, indicating the response correlates with peptide dose relative to size of animal. These results suggest that peptide antigens targeted to produce B cell mediated response may result in increased incidence of type III hypersensitivity reactions when delivered in non-depot forming vaccines. The DPX formulation induced strong antibody titres to the antigen without causing adverse events, likely due to the strength of the depot in vivo, and demonstrates the potential safety and immunogenicity of this platform for B cell peptide antigens.
Collapse
Affiliation(s)
| | - Alecia MacKay
- a Immunovaccine Inc. , Halifax , Nova Scotia , Canada
| | | | | | | | | | - Joanne M Langley
- b Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority , Dalhousie University , Halifax , Nova Scotia , Canada.,c Department of Pediatrics , Dalhousie University , Halifax , Nova Scotia , Canada.,d Community Health and Epidemiology , Dalhousie University , Halifax , Nova Scotia , Canada
| | - Scott Halperin
- b Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority , Dalhousie University , Halifax , Nova Scotia , Canada.,c Department of Pediatrics , Dalhousie University , Halifax , Nova Scotia , Canada.,e Microbiology and Immunology , Dalhousie University , Halifax , Nova Scotia , Canada
| | - Marc Mansour
- a Immunovaccine Inc. , Halifax , Nova Scotia , Canada
| | - Marianne M Stanford
- a Immunovaccine Inc. , Halifax , Nova Scotia , Canada.,b Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority , Dalhousie University , Halifax , Nova Scotia , Canada.,e Microbiology and Immunology , Dalhousie University , Halifax , Nova Scotia , Canada
| |
Collapse
|
14
|
Weir GM, Karkada M, Hoskin D, Stanford MM, MacDonald L, Mansour M, Liwski RS. Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo. PLoS One 2017; 12:e0180073. [PMID: 28662082 PMCID: PMC5491120 DOI: 10.1371/journal.pone.0180073] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Accepted: 06/11/2017] [Indexed: 12/13/2022] Open
Abstract
Vaccines that can rapidly induce strong and robust antibody-mediated immunity could improve protection from certain infectious diseases for which current vaccine formulations are inefficient. For indications such as anthrax and influenza, antibody production in vivo is a correlate of efficacy. Toll-like receptor (TLR) agonists are frequently studied for their role as vaccine adjuvants, largely because of their ability to enhance initiation of immune responses to antigens by activating dendritic cells. However, TLRs are also expressed on B cells and may contribute to effective B cell activation and promote differentiation into antigen-specific antibody producing plasma cells in vivo. We sought to discover an adjuvant system that could be used to augment antibody responses to influenza and anthrax vaccines. We first characterized an adjuvant system in vitro which consisted of two TLR ligands, poly I:C (TLR3) and Pam3CSK4 (TLR2), by evaluating its effects on B cell activation. Each agonist enhanced B cell activation through increased expression of surface receptors, cytokine secretion and proliferation. However, when B cells were stimulated with poly I:C and Pam3CSK4 in combination, further enhancement to cell activation was observed. Using B cells isolated from knockout mice we confirmed that poly I:C and Pam3CSK4 were signaling through TLR3 and TLR2, respectively. B cells activated with Poly I:C and Pam3CSK4 displayed enhanced capacity to stimulate allogeneic CD4+ T cell activation and differentiate into antibody-producing plasma cells in vitro. Mice vaccinated with influenza or anthrax antigens formulated with poly I:C and Pam3CSK4 in DepoVax™ vaccine platform developed a rapid and strong antigen-specific serum antibody titer that persisted for at least 12 weeks after a single immunization. These results demonstrate that combinations of TLR adjuvants promote more effective B cell activation in vitro and can be used to augment antibody responses to vaccines in vivo.
Collapse
Affiliation(s)
- Genevieve M. Weir
- Research & Development, Immunovaccine Inc, Halifax, Nova Scotia, Canada
- Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada
- * E-mail:
| | - Mohan Karkada
- Research & Development, Immunovaccine Inc, Halifax, Nova Scotia, Canada
- Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada
| | - David Hoskin
- Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada
- Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Marianne M. Stanford
- Research & Development, Immunovaccine Inc, Halifax, Nova Scotia, Canada
- Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Lisa MacDonald
- Research & Development, Immunovaccine Inc, Halifax, Nova Scotia, Canada
| | - Marc Mansour
- Research & Development, Immunovaccine Inc, Halifax, Nova Scotia, Canada
| | - Robert S. Liwski
- Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada
- Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada
- Department of Pathology and Laboratory Medicine, Division of Hematopathology, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
| |
Collapse
|
15
|
Delcommenne MC, Hrytsenko O, Tram C, Weir G, Stanford MM. The QuickSwitch Quant HLA-A*02:01 Tetramer Kit can be used for determining the biological activity of a cancer vaccine. The Journal of Immunology 2017. [DOI: 10.4049/jimmunol.198.supp.79.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
We have devised a fast and user-friendly assay (QuickSwitch™ Quant) that can both help determine binding of novel peptides to MHC class I molecules and generate new specificity MHC class I tetramers for peptide specific T cell detection. This study aimed to determine whether the QuickSwitch™ Quant HLA-A*02:01 Tetramer Kit can also be used for evaluating the biological activity of a vaccine. The tested vaccine was DPX-Survivac, an ovarian cancer vaccine candidate which consists of several survivin peptide antigens that are each restricted to a different human class I allele. We sought to evaluate the specificity and sensitivity of the QuickSwitch™ Quant HLA-A* 02:01 Tetramer Kit-PE for assessing the biological activity of SurA2.M, an HLA-A2-restricted peptide, in DPX-Survivac. The complete vaccine also contains non-HLA-A2 restricted peptides, lipids and a polynucleotide adjuvant. We tested the detection of the peptide prepared individually in a buffered solution or in the DPX-Survivac vaccine prepared in an aqueous formulation. Results indicate that peptide exchange rate of SurA2.M is similar whether it is dissolved individually in a buffered solution or mixed with other components of the vaccine. Results also may be dependent on the affinity of the peptide for HLA-A2. Thus, by optimizing a concentration curve using individual peptides, the QuickSwitch™ Quant HLA-A*02:01 Tetramer Kit can be used to quantify the concentration of HLA-A2 restricted peptides in simple solutions or more complex formulations.
Collapse
|
16
|
Weir GM, Hrytsenko O, Quinton T, Berinstein NL, Stanford MM, Mansour M. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. J Immunother Cancer 2016; 4:68. [PMID: 27777777 PMCID: PMC5067905 DOI: 10.1186/s40425-016-0169-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2016] [Accepted: 09/21/2016] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND Future cancer immunotherapies will combine multiple treatments to generate functional immune responses to cancer antigens through synergistic, multi-modal mechanisms. In this study we explored the combination of three distinct immunotherapies: a class I restricted peptide-based cancer vaccine, metronomic cyclophosphamide (mCPA) and anti-PD-1 treatment in a murine tumor model expressing HPV16 E7 (C3). METHODS Mice were implanted with C3 tumors subcutaneously. Tumor bearing mice were treated with mCPA (20 mg/kg/day PO) for seven continuous days on alternating weeks, vaccinated with HPV16 E749-57 peptide antigen formulated in the DepoVax (DPX) adjuvanting platform every second week, and administered anti-PD-1 (200 μg/dose IP) after each vaccination. Efficacy was measured by following tumor growth and survival. Immunogenicity was measured by IFN-γ ELISpot of spleen, vaccine draining lymph nodes and tumor draining lymph nodes. Tumor infiltration was measured by flow cytometry for CD8α+ peptide-specific T cells and RT-qPCR for cytotoxic proteins. The clonality of tumor infiltrating T cells was measured by TCRβ sequencing using genomic DNA. RESULTS Untreated C3 tumors had low expression of PD-L1 in vivo and anti-PD-1 therapy alone provided no protection from tumor growth. Treatment with DPX/mCPA could delay tumor growth, and tri-therapy with DPX/mCPA/anti-PD-1 provided long-term control of tumors. We found that treatment with DPX/mCPA/anti-PD-1 enhanced systemic antigen-specific immune responses detected in the spleen as determined by IFN-γ ELISpot compared to those in the DPX/mCPA group, but immune responses in tumor-draining lymph nodes were not increased. Although no increases in antigen-specific CD8α+ TILs could be detected, there was a trend for increased expression of cytotoxic genes within the tumor microenvironment as well as an increase in clonality in mice treated with DPX/mCPA/anti-PD-1 compared to those with anti-PD-1 alone or DPX/mCPA. Using a library of antigen-specific CD8α+ T cell clones, we found that antigen-specific clones were more frequently expanded in the DPX/mCPA/anti-PD-1 treated group. CONCLUSIONS These results demonstrate how the efficacy of anti-PD-1 may be improved by combination with a potent and targeted T cell activating immune therapy.
Collapse
MESH Headings
- Administration, Metronomic
- Animals
- Antineoplastic Agents, Immunological/pharmacology
- Antineoplastic Agents, Immunological/therapeutic use
- B7-H1 Antigen/genetics
- B7-H1 Antigen/metabolism
- CD8-Positive T-Lymphocytes/drug effects
- CD8-Positive T-Lymphocytes/immunology
- CD8-Positive T-Lymphocytes/metabolism
- Cancer Vaccines/immunology
- Cell Line, Tumor
- Clonal Evolution/drug effects
- Clonal Evolution/immunology
- Cyclophosphamide/administration & dosage
- Cytotoxicity, Immunologic
- Disease Models, Animal
- Epitopes, T-Lymphocyte/chemistry
- Epitopes, T-Lymphocyte/immunology
- Female
- Gene Expression
- Humans
- Immunomodulation/drug effects
- Lymphocytes, Tumor-Infiltrating/drug effects
- Lymphocytes, Tumor-Infiltrating/immunology
- Lymphocytes, Tumor-Infiltrating/metabolism
- Mice
- Neoplasms/immunology
- Neoplasms/metabolism
- Neoplasms/pathology
- Neoplasms/therapy
- Programmed Cell Death 1 Receptor/antagonists & inhibitors
- Programmed Cell Death 1 Receptor/genetics
- Programmed Cell Death 1 Receptor/metabolism
- T-Cell Antigen Receptor Specificity/drug effects
- T-Cell Antigen Receptor Specificity/immunology
- T-Lymphocyte Subsets/drug effects
- T-Lymphocyte Subsets/immunology
- T-Lymphocyte Subsets/metabolism
- Tumor Microenvironment/drug effects
- Tumor Microenvironment/immunology
Collapse
Affiliation(s)
| | - Olga Hrytsenko
- Immunovaccine Inc., 1344 Summer St., Halifax, NS B3H 0A8 Canada
| | - Tara Quinton
- Immunovaccine Inc., 1344 Summer St., Halifax, NS B3H 0A8 Canada
| | - Neil L. Berinstein
- Sunnybrook Research Institute, 2075 Bayview Ave., Toronto, ON M4N 3M5 Canada
- University of Toronto, 27 King’s College Cir, Toronto, ON M5S 1A1 Canada
| | - Marianne M. Stanford
- Immunovaccine Inc., 1344 Summer St., Halifax, NS B3H 0A8 Canada
- Department of Microbiology & Immunology, Dalhousie University, 5850 College St., Room 7C, Halifax, NS B3H 4R2 Canada
| | - Marc Mansour
- Immunovaccine Inc., 1344 Summer St., Halifax, NS B3H 0A8 Canada
| |
Collapse
|
17
|
DeBay DR, Brewer KD, LeBlanc SA, Weir GM, Stanford MM, Mansour M, Bowen CV. Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. Mol Ther Methods Clin Dev 2015; 2:15048. [PMID: 26730395 PMCID: PMC4685660 DOI: 10.1038/mtm.2015.48] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Revised: 10/07/2015] [Accepted: 10/07/2015] [Indexed: 12/16/2022]
Abstract
In the preclinical development of immunotherapy candidates, understanding the mechanism of action and determining biomarkers that accurately characterize the induced host immune responses is critical to improving their clinical interpretation. Magnetic resonance imaging (MRI) was used to evaluate in vivo changes in lymph node size in response to a peptide-based cancer vaccine therapy, formulated using DepoVax (DPX). DPX is a novel adjuvant lipid-in-oil-based formulation that facilitates enhanced immune responses by retaining antigens at the injection site for extended latencies, promoting increased potentiation of immune cells. C57BL/6 mice were implanted with C3 (HPV) tumor cells and received either DPX or control treatments, 5 days post-implantation. Complete tumor eradication occurred in DPX-vaccinated animals and large volumetric increases were observed in the vaccine-draining right inguinal lymph node (VRILN) in DPX mice, likely corresponding to increased localized immune response to the vaccine. Upon evaluating the relative measure of vaccine-potentiated immune activation to tumor-induced immune response (VRILN/VLILN), receiver-operating characteristic (ROC) curves revealed an area under the curve (AUC) of 0.90 (±0.07), indicating high specificity and sensitivity as a predictive biomarker of vaccine efficacy. We have determined that for this tumor model, early MRI lymph node volumetric changes are predictive of depot immunotherapeutic success.
Collapse
Affiliation(s)
- Drew R DeBay
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, Nova Scotia, Canada
| | - Kimberly D Brewer
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, Nova Scotia, Canada
- Immunovaccine Inc., Halifax, Nova Scotia, Canada
- Department of Radiology, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Sarah A LeBlanc
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, Nova Scotia, Canada
| | | | | | - Marc Mansour
- Immunovaccine Inc., Halifax, Nova Scotia, Canada
| | - Chris V Bowen
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, Nova Scotia, Canada
- Department of Radiology, Dalhousie University, Halifax, Nova Scotia, Canada
| |
Collapse
|
18
|
Hrytsenko O, Weir GM, Karkada M, Berinstein NL, Stanford MM, Mansour M. Abstract POSTER-THER-1415: Translational study of DPX-survivac peptide vaccine and metronomic cyclophosphamide using a novel HLA-A2/ survivin expressing ovarian tumor model to mimic phase I clinical data. Clin Cancer Res 2015. [DOI: 10.1158/1557-3265.ovcasymp14-poster-ther-1415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Survivin, a member of the inhibitors of the apoptosis protein family, is involved in critical pathways of cancer cell growth and survival. Survivin overexpression is detected in 90% of epithelial ovarian cancers. DPX-Survivac is a peptide vaccine containing five survivin HLA class I peptides (A1, A2, A3, A24 and B7) and a universal HLA class II helper peptide derived from tetanus toxin (A16L) formulated in the novel adjuvanting vaccine platform DepoVaxTM. In a phase I clinical study DPX-Survivac was combined with a continuous (metronomic) low dose of cyclophosphamide (mCPA) to treat patients with advanced or recurrent ovarian cancer. In this study, we found mCPA significantly enhanced the immune responses induced by DPX-Survivac.
In order to investigate this effect and to understand the mechanisms involved, we developed an ovarian tumor model in HLA-A2 transgenic mice. Vaccination of HLA-A2 transgenic mice generates an immune response towards the A2-restricted survivin peptide in DPX-Survivac. Mouse Ovarian Surface Epithelial (MOSE) cell lines are “natural” ovarian cancer models established by spontaneous in vitro transformation of primary ovarian surface epithelial cells. MOSE cell lines were confirmed to express HLA-A2 and overexpress survivin, and formed subcutaneous and intraperitoneal ovarian tumors when implanted into syngeneic recipients.
HLA-A2 transgenic mice bearing MOSE tumors were treated with either DPX-Survivac, mCPA (administrated at 20 mg/kg/day in drinking water) or a combination of mCPA and DPX-Survivac. We found that combining DPX-Survivac with mCPA provided most effective control of tumor growth. Ex vivo IFN-γ ELISPOT revealed that mCPA increases immunogenicity of the DPX-Survivac in mice bearing MOSE tumors. Analysis of the blood and tumor microenvironment by RT-qPCR showed that mice treated with the combination therapy had an altered immune gene signature with increased cytotoxic T lymphocyte markers compared to mice treated with DPX-Survivac or metronomic cyclophosphamide alone. Our data indicates that the combination treatment enhances the infiltration of CD8+ T cells into tumors, enhancing tumor specific immune responses.
In summary, we have established a new model of epithelial ovarian cancer in HLA-A2 transgenic mice. This model was used to investigate the immunogenicity and efficacy of DPX-Survivac, an HLA-restricted peptide vaccine with proven immunogenicity in human clinical trials, in combination with the immune modulator mCPA. This model can be used to explore mechanisms of establishment and progression of ovarian cancer as well as for evaluation of new treatment strategies including new immune modulator/ vaccine combinations.
Citation Format: Olga Hrytsenko, Genevieve M. Weir, Mohan Karkada, Neil L. Berinstein, Marianne M. Stanford, Marc Mansour. Translational study of DPX-survivac peptide vaccine and metronomic cyclophosphamide using a novel HLA-A2/ survivin expressing ovarian tumor model to mimic phase I clinical data [abstract]. In: Proceedings of the 10th Biennial Ovarian Cancer Research Symposium; Sep 8-9, 2014; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(16 Suppl):Abstract nr POSTER-THER-1415.
Collapse
Affiliation(s)
| | - Genevieve M. Weir
- 1Immunovaccine Inc., Halifax, NS
- 2Dept. Microbiology & Immunology, Dalhousie University, Halifax, NS
| | - Mohan Karkada
- 1Immunovaccine Inc., Halifax, NS
- 2Dept. Microbiology & Immunology, Dalhousie University, Halifax, NS
| | - Neil L. Berinstein
- 1Immunovaccine Inc., Halifax, NS
- 3Ontario Institute for Cancer Research, MaRS Centre, Toronto, ON
| | - Marianne M. Stanford
- 1Immunovaccine Inc., Halifax, NS
- 2Dept. Microbiology & Immunology, Dalhousie University, Halifax, NS
| | | |
Collapse
|
19
|
Berinstein NL, Karkada M, Oza AM, Odunsi K, Villella JA, Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald LD, Quinton T, Rajagopalan R, Sharp K, Penwell A, Sammatur L, Burzykowski T, Stanford MM, Mansour M. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology 2015; 4:e1026529. [PMID: 26405584 PMCID: PMC4570133 DOI: 10.1080/2162402x.2015.1026529] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2015] [Revised: 02/26/2015] [Accepted: 02/27/2015] [Indexed: 11/27/2022] Open
Abstract
DepoVax™ is an innovative and strongly immunogenic vaccine platform. Survivin is highly expressed in many tumor types and has reported prognostic value. To generate tumor-specific immune response, a novel cancer vaccine was formulated in DepoVax platform (DPX-Survivac) using survivin HLA class I peptides. Safety and immune potency of DPX-Survivac was tested in combination with immune-modulator metronomic cyclophosphamide in ovarian cancer patients. All the patients receiving the therapy produced antigen-specific immune responses; higher dose vaccine and cyclophosphamide treatment generating significantly higher magnitude responses. Strong T cell responses were associated with differentiation of naïve T cells into central/effector memory (CM/EM) and late differentiated (LD) polyfunctional antigen-specific CD4+ and CD8+ T cells. This approach enabled rapid de novo activation/expansion of vaccine antigen-specific CD8+ T cells and provided a strong rationale for further testing to determine clinical benefits associated with this immune activation. These data represent vaccine-induced T cell activation in a clinical setting to a self-tumor antigen previously described only in animal models.
Collapse
Affiliation(s)
| | | | - Amit M Oza
- Princess Margaret Cancer Center; University Health Network ; Toronto, Ontario, Canada
| | | | | | | | | | - Tanja Pejovic
- Oregon Health & Science University ; Portland, OR USA
| | - James Bentley
- QEII Health Sciences Center ; Halifax, Nova Scotia, Canada
| | - Marc Buyse
- International Drug Development Institute (IDDI) ; Louvain la Neuve, Belgium
| | - Rita Nigam
- Immunovaccine, Inc. ; Halifax, Nova Scotia, Canada
| | | | | | - Tara Quinton
- Immunovaccine, Inc. ; Halifax, Nova Scotia, Canada
| | | | | | | | | | - Tomasz Burzykowski
- International Drug Development Institute (IDDI) ; Louvain la Neuve, Belgium
| | | | - Marc Mansour
- Immunovaccine, Inc. ; Halifax, Nova Scotia, Canada
| |
Collapse
|
20
|
Weir GM, Hrytsenko O, Stanford MM, Berinstein NL, Karkada M, Liwski RS, Mansour M. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. Oncoimmunology 2014; 3:e953407. [PMID: 25960932 PMCID: PMC4368141 DOI: 10.4161/21624011.2014.953407] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2014] [Accepted: 06/24/2014] [Indexed: 12/22/2022] Open
Abstract
In clinical trials, metronomic cyclophosphamide (CPA) is increasingly being combined with vaccines to reduce tumor-induced immune suppression. Previous strategies to modulate the immune system during vaccination have involved continuous administration of low dose chemotherapy, studies that have posed unique considerations for clinical trial design. Here, we evaluated metronomic CPA in combination with a peptide vaccine targeting HPV16E7 in an HPV16-induced tumor model, focusing on the cytotoxic T-cell response and timing of low dose metronomic CPA (mCPA) treatment relative to vaccination. Mice bearing C3 tumors were given metronomic CPA on alternating weeks in combination with immunization with a DepoVax vaccine containing HPV16E749-57 peptide antigen every 3 weeks. Only the combination therapy provided significant long-term control of tumor growth. The efficacy of the vaccine was uncompromised if given at the beginning or end of a cycle of metronomic CPA. Metronomic CPA had a pronounced lymphodepletive effect on the vaccine draining lymph node, yet did not reduce the development of antigen-specific CD8+ T cells induced by vaccination. This enrichment correlated with increased cytotoxic activity in the spleen and increased expression of cytotoxic gene signatures in the tumor. Immunity could be passively transferred through CD8+ T cells isolated from tumor-bearing mice treated with the combinatorial treatment regimen. A comprehensive survey of splenocytes indicated that metronomic CPA, in the absence of vaccination, induced transient lymphodepletion marked by a selective expansion of myeloid-derived suppressor cells. These results provide important insights into the multiple mechanisms of metronomic CPA induced immune modulation in the context of a peptide cancer vaccine that may be translated into more effective clinical trial designs.
Collapse
Key Words
- CPA, cyclophosphamide
- CTL, cytotoxic T lymphocyte
- CTLA-4, cytotoxic T lymphocyte-associated protein 4
- DPX, DepoVax
- HPV, human papilloma virus
- HPV16
- IFNγ, interferon γ
- MDSC, myeloid-derived suppressor cells
- PD-1/PDCD1, programmed cell death 1
- PO, per os (oral)
- Treg, regulatory T cell
- cancer
- checkpoint inhibitors
- mCPA, metronomic low dose CPA
- metronomic cyclophosphamide
- sbCPA, single bolus low dose CPA
- translational
- vaccine
Collapse
Affiliation(s)
- Genevieve M Weir
- Immunovaccine Inc. ; Halifax; Nova Scotia, Canada ; Department of Microbiology & Immunology; Dalhousie University ; Halifax; Nova Scotia, Canada
| | - Olga Hrytsenko
- Immunovaccine Inc. ; Halifax; Nova Scotia, Canada ; Department of Biology; Dalhousie University ; Halifax; Nova Scotia, Cananda
| | - Marianne M Stanford
- Immunovaccine Inc. ; Halifax; Nova Scotia, Canada ; Department of Microbiology & Immunology; Dalhousie University ; Halifax; Nova Scotia, Canada
| | | | - Mohan Karkada
- Immunovaccine Inc. ; Halifax; Nova Scotia, Canada ; Department of Microbiology & Immunology; Dalhousie University ; Halifax; Nova Scotia, Canada
| | - Robert S Liwski
- Department of Microbiology & Immunology; Dalhousie University ; Halifax; Nova Scotia, Canada ; Division of Hematopathology; Queen Elizabeth II Health Sciences Centre ; Nova Scotia, Canada
| | - Marc Mansour
- Immunovaccine Inc. ; Halifax; Nova Scotia, Canada
| |
Collapse
|
21
|
Brewer KD, Lake K, Pelot N, Stanford MM, DeBay DR, Penwell A, Weir GM, Karkada M, Mansour M, Bowen CV. Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI. Vaccine 2014; 32:6956-6962. [PMID: 25444822 DOI: 10.1016/j.vaccine.2014.10.058] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Revised: 09/16/2014] [Accepted: 10/20/2014] [Indexed: 01/26/2023]
Abstract
Immunotherapies, including peptide-based vaccines, are a growing area of cancer research, and understanding their mechanism of action is crucial for their continued development and clinical application. Exploring the biodistribution of vaccine components may be key to understanding this action. This work used magnetic resonance imaging (MRI) to characterize the in vivo biodistribution of the antigen and oil substrate of the vaccine delivery system known as DepoVax(TM). DepoVax uses a novel adjuvanted lipid-in-oil based formulation to solubilise antigens and promote a depot effect. In this study, antigen or oil were tagged with superparamagnetic iron oxide (SPIO), making them visible on MR images. This enables tracking of individual vaccine components to determine changes in biodistribution. Mice were injected with SPIO-labeled antigen or SPIO-labeled oil, and imaged to examine clearance of labeled components from the vaccine site. The SPIO-antigen was steadily cleared, with nearly half cleared within two months post-vaccination. In contrast, the SPIO-oil remained relatively unchanged. The biodistribution of the SPIO-antigen component within the vaccine site was heterogeneous, indicating the presence of active clearance mechanisms, rather than passive diffusion or drainage. Mice injected with SPIO-antigen also showed MRI contrast for several weeks post-vaccination in the draining inguinal lymph node. These results indicate that MRI can visualize the in vivo longitudinal biodistribution of vaccine components. The sustained clearance is consistent with antigen up-take and trafficking by immune cells, leading to accumulation in the draining lymph node, which corresponds to the sustained immune responses and reduced tumor burden observed in vaccinated mice.
Collapse
Affiliation(s)
- Kimberly D Brewer
- Immunovaccine Inc., Halifax, NS, Canada; School of Biomedical Engineering, Dalhousie University, Halifax, NS, Canada
| | - Kerry Lake
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada
| | - Nicole Pelot
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada
| | - Marianne M Stanford
- Immunovaccine Inc., Halifax, NS, Canada; Department of Microbiology & Immunology, Dalhousie University, Halifax, NS, Canada
| | - Drew R DeBay
- Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada
| | | | - Genevieve M Weir
- Immunovaccine Inc., Halifax, NS, Canada; Department of Microbiology & Immunology, Dalhousie University, Halifax, NS, Canada
| | - Mohan Karkada
- Immunovaccine Inc., Halifax, NS, Canada; Department of Microbiology & Immunology, Dalhousie University, Halifax, NS, Canada
| | | | - Chris V Bowen
- School of Biomedical Engineering, Dalhousie University, Halifax, NS, Canada; Biomedical Translational Imaging Centre (BIOTIC), Halifax, NS, Canada; Departments of Radiology and Physics, Dalhousie University, Halifax, NS, Canada.
| |
Collapse
|
22
|
Weir GM, Berinstein NL, Hrytsenko O, Karkada M, Stanford MM, Mansour M. Abstract A84: Metronomic cyclophosphamide, when combined with vaccination, increases the immunogenicity of the vaccine and modulates the tumor microenvironment to provide better anti-tumor activity. Clin Cancer Res 2013. [DOI: 10.1158/1078-0432.ovca13-a84] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
DPX-Survivac is a peptide vaccine targeting the broadly expressed tumor antigen survivin. The vaccine contains a mixture of survivin HLA class I peptides (A1, A2, A3, A24 and B7) formulated in the novel adjuvanting vaccine platform DepoVaxTM. A phase I clinical study performed in advanced ovarian cancer patients (n=19) demonstrated that the combination of metronomic cyclophosphamide (mCPA) and DPX-Survivac exhibited enhanced immune responses by IFN-γ ELISPOT (p<0.015) and increased poly-functional antigen-specific EM/ CM CD8+ T cells, relative to patients treated with vaccine alone. These results were mirrored in a preclinical mouse model in which tumor bearing mice treated with mCPA in combination with a DPX peptide vaccine had increased IFN-γ ELISPOT response and enriched antigen-specific CD8+ T cells. Adoptively transferred T cells from mice treated with the combination of mCPA and vaccine provided a more pronounced anti-tumor effect. Immunophenotyping by flow cytometry indicated that mice treated with mCPA and vaccine had reduced levels of tumor-induced immune suppressor cells, such as myeloid derived suppressor cells, but no effect was seen on regulatory T cells. Analysis of the tumor microenvironment by RT-qPCR revealed that mice treated with combination therapy had increased levels of cytotoxic T lymphocyte (CTL) markers such as granzyme B and IFN-γ. An ovarian tumor model (MOSE) was developed in HLA-A2 transgenic mice to extend these finding to a DPX-survivin vaccine in a relevant animal model. We showed that mCPA increased the levels of CTL markers in the tumor specifically when combined with a DPX-survivin vaccine, in addition to enhancing the immunogenicity of the vaccine. Together, these models allow us to explore novel immune modulator/ vaccine combinations and provide insight into mechanisms that could result in enhanced anti-tumor activity.
Citation Format: Genevieve M. Weir, Neil L. Berinstein, Olga Hrytsenko, Mohan Karkada, Marianne M. Stanford, Marc Mansour. Metronomic cyclophosphamide, when combined with vaccination, increases the immunogenicity of the vaccine and modulates the tumor microenvironment to provide better anti-tumor activity. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: From Concept to Clinic; Sep 18-21, 2013; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2013;19(19 Suppl):Abstract nr A84.
Collapse
|
23
|
Weir GM, Stanford MM, Berinstein NL, Karkada M, Liwski RS, Mansour M. Abstract 2836: Metronomic cyclophosphamide enhances antitumor immune response induced by a DepoVaxTM-based peptide vaccine. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-2836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Advanced cancers utilize several mechanisms to escape immune-mediated detection and destruction thus reducing the effectiveness of cancer therapeutics on multiple levels. Low dose cyclophosphamide (CPA) has been investigated as an immune modulator to potentiate active immune response towards tumor cells, but a single bolus injection of CPA has been ineffective at boosting response to cancer vaccines in most clinical trials. We sought to determine if a metronomic regimen of low dose CPA (mCPA) could enhance the efficacy of a peptide-based vaccine formulated in DepoVaxTM (DPX). DPX is a novel vaccine platform comprised of liposomes in oil that is formulated with an adjuvant, universal T-helper peptide and specific tumor peptide antigens. Using a murine tumor model (C3) we tested the benefit of combining mCPA and vaccination for controlling well established subcutaneous solid tumors in vivo. Mice were treated starting 5 days after C3 tumor implantation with mCPA administered in drinking water in a one week on/ off schedule and vaccinated every 3 weeks. In this model, neither mCPA nor vaccine treatments alone were sufficient to eradicate advanced tumors. However, combining mCPA with vaccination provided effective tumor control. Ex vivo analysis of immune response after a single treatment of mCPA combined with vaccine showed a significant increase in antigen-specific IFN-γ release by ELISPOT, which became more pronounced after multiple rounds of treatment in tumor bearing mice. This immune response was accompanied by a corresponding increase in antigen-specific cytotoxic T cell activity as measured by in vivo CTL assay. Dextramer analysis of the antigen-specific CD8+ T cells in the vaccine-draining lymph node revealed that while the total number of CD8+ T cells decreased with mCPA treatment, the number of antigen-specific CD8+ T cells was increased by vaccination and not reduced by mCPA. Flow cytometric analysis of splenocyte cell populations did not show any significant reduction in CD4+CD25hiFoxP3+Treg populations due to mCPA treatment, as previously reported by others, but we did find an increase in myeloid-derived suppressor cells due to mCPA treatment that was decreased in mice treated with both mCPA & vaccination. Finally, adoptive transfer of T cells from tumor bearing mice treated with mCPA & vaccination significantly reduced tumor growth in tumor challenged recipients. Overall, our data indicate that mCPA combines with a peptide based DPX vaccine to enhance the T cell response to antigen that ultimately results in an improved immunotherapy for cancer. The immune-enhancing effects of mCPA in this model are multi-faceted and augment the T cell responses independent of direct cytotoxic effects on the tumor. The results of this pre-clinical study have assisted in the designing of a phase II clinical trial for DPX-Survivac vaccine in combination with mCPA in ovarian cancer patients.
Citation Format: Genevieve M. Weir, Marianne M. Stanford, Neil L. Berinstein, Mohan Karkada, Robert S. Liwski, Marc Mansour. Metronomic cyclophosphamide enhances antitumor immune response induced by a DepoVaxTM-based peptide vaccine. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2836. doi:10.1158/1538-7445.AM2013-2836
Collapse
Affiliation(s)
| | | | | | | | | | - Marc Mansour
- 1Immunovaccine Inc., Halifax, Nova Scotia, Canada
| |
Collapse
|
24
|
Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, Weir GM, Stanford MM, Mansour M. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med 2012; 10:156. [PMID: 22862954 PMCID: PMC3479010 DOI: 10.1186/1479-5876-10-156] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2012] [Accepted: 07/11/2012] [Indexed: 11/20/2022] Open
Abstract
Background DepoVaxTM is a novel non-emulsion depot-forming vaccine platform with the capacity to significantly enhance the immunogenicity of peptide cancer antigens. Naturally processed HLA-A2 restricted peptides presented by breast, ovarian and prostate cancer cells were used as antigens to create a therapeutic cancer vaccine, DPX-0907. Methods A phase I clinical study was designed to examine the safety and immune activating potential of DPX-0907 in advanced stage breast, ovarian and prostate cancer patients. A total of 23 late stage cancer patients were recruited and were divided into two dose/volume cohorts in a three immunization protocol. Results DPX-0907 was shown to be safe with injection site reactions being the most commonly reported adverse event. All breast cancer patients (3/3), most of ovarian (5/6) and one third of prostate (3/9) cancer patients exhibited detectable immune responses, resulting in a 61% immunological response rate. Immune responses were generally observed in patients with better disease control after their last prior treatment. Antigen-specific responses were detected in 73% of immune responders (44% of evaluable patients) after the first vaccination. In 83% of immune responders (50% of evaluable patients), peptide-specific T cell responses were detected at ≥2 time points post vaccination with 64% of the responders (39% of evaluable patients) showing evidence of immune persistence. Immune monitoring also demonstrated the generation of antigen-specific T cell memory with the ability to secrete multiple Type 1 cytokines. Conclusions The novel DepoVax formulation promotes multifunctional effector memory responses to peptide-based tumor associated antigens. The data supports the capacity of DPX-0907 to elicit Type-1 biased immune responses, warranting further clinical development of the vaccine. This study underscores the importance of applying vaccines in clinical settings in which patients are more likely to be immune competent. Trial Registration ClinicalTrials.gov NCT01095848
Collapse
|
25
|
Rintoul JL, Lemay CG, Tai LH, Stanford MM, Falls TJ, de Souza CT, Bridle BW, Daneshmand M, Ohashi PS, Wan Y, Lichty BD, Mercer AA, Auer RC, Atkins HL, Bell JC. ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic. Mol Ther 2012; 20:1148-57. [PMID: 22273579 PMCID: PMC3369287 DOI: 10.1038/mt.2011.301] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2011] [Accepted: 12/18/2011] [Indexed: 12/27/2022] Open
Abstract
Replicating viruses for the treatment of cancer have a number of advantages over traditional therapeutic modalities. They are highly targeted, self-amplifying, and have the added potential to act as both gene-therapy delivery vehicles and oncolytic agents. Parapoxvirus ovis or Orf virus (ORFV) is the prototypic species of the Parapoxvirus genus, causing a benign disease in its natural ungulate host. ORFV possesses a number of unique properties that make it an ideal viral backbone for the development of a cancer therapeutic: it is safe in humans, has the ability to cause repeat infections even in the presence of antibody, and it induces a potent T(h)-1-dominated immune response. Here, we show that live replicating ORFV induces an antitumor immune response in multiple syngeneic mouse models of cancer that is mediated largely by the potent activation of both cytokine-secreting, and tumoricidal natural killer (NK) cells. We have also highlighted the clinical potential of the virus by demonstration of human cancer cell oncolysis including efficacy in an A549 xenograft model of cancer.
Collapse
Affiliation(s)
- Julia L Rintoul
- Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Centre for Innovative Cancer Research, Ottawa, Ontario, Canada
| | - Chantal G Lemay
- Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Centre for Innovative Cancer Research, Ottawa, Ontario, Canada
| | - Lee-Hwa Tai
- Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Centre for Innovative Cancer Research, Ottawa, Ontario, Canada
| | - Marianne M Stanford
- Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Centre for Innovative Cancer Research, Ottawa, Ontario, Canada
| | - Theresa J Falls
- Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Centre for Innovative Cancer Research, Ottawa, Ontario, Canada
| | - Christiano T de Souza
- Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Centre for Innovative Cancer Research, Ottawa, Ontario, Canada
| | - Byram W Bridle
- Department of Pathology and Molecular Medicine, Centre for Gene Therapeutics, McMaster University, Faculty of Health Sciences, Hamilton, Ontario, Canada
| | - Manijeh Daneshmand
- Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Centre for Innovative Cancer Research, Ottawa, Ontario, Canada
| | - Pamela S Ohashi
- The Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute/Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
- Department of Immunology, University of Toronto, Toronto, Ontario, Canada
| | - Yonghong Wan
- Department of Pathology and Molecular Medicine, Centre for Gene Therapeutics, McMaster University, Faculty of Health Sciences, Hamilton, Ontario, Canada
| | - Brian D Lichty
- Department of Pathology and Molecular Medicine, Centre for Gene Therapeutics, McMaster University, Faculty of Health Sciences, Hamilton, Ontario, Canada
| | - Andrew A Mercer
- Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand
| | - Rebecca C Auer
- Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Centre for Innovative Cancer Research, Ottawa, Ontario, Canada
| | - Harold L Atkins
- Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Centre for Innovative Cancer Research, Ottawa, Ontario, Canada
| | - John C Bell
- Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Centre for Innovative Cancer Research, Ottawa, Ontario, Canada
| |
Collapse
|
26
|
Breitbach CJ, De Silva NS, Falls TJ, Aladl U, Evgin L, Paterson J, Sun YY, Roy DG, Rintoul JL, Daneshmand M, Parato K, Stanford MM, Lichty BD, Fenster A, Kirn D, Atkins H, Bell JC. Targeting tumor vasculature with an oncolytic virus. Mol Ther 2011; 19:886-94. [PMID: 21364541 DOI: 10.1038/mt.2011.26] [Citation(s) in RCA: 137] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Oncolytic viruses (OVs) have been engineered or selected for cancer cell-specific infection however, we have found that following intravenous administration of vesicular stomatitis virus (VSV), tumor cell killing rapidly extends far beyond the initial sites of infection. We show here for the first time that VSV directly infects and destroys tumor vasculature in vivo but leaves normal vasculature intact. Three-dimensional (3D) reconstruction of infected tumors revealed that the majority of the tumor mass lacks significant blood flow in contrast to uninfected tumors, which exhibit relatively uniform perfusion. VSV replication in tumor neovasculature and spread within the tumor mass, initiates an inflammatory reaction including a neutrophil-dependent initiation of microclots within tumor blood vessels. Within 6 hours of intravenous administration of VSV and continuing for at least 24 hours, we observed the initiation of blood clots within the tumor vasculature whereas normal vasculature remained clot free. Blocking blood clot formation with thrombin inhibitors prevented tumor vascular collapse. Our results demonstrate that the therapeutic activity of an OV can go far beyond simple infection and lysis of malignant cells.
Collapse
Affiliation(s)
- Caroline J Breitbach
- Centre for Cancer Therapeutics, Ottawa Health Research Institute, Ottawa, Ontario, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
The use of viruses as targeted cancer therapy has shown significant promise, and the list of oncolytic viruses continue to grow. The interest in unexplored viruses as oncolytic agents is a natural corollary to the successes and challenges of those already being examined in the clinical setting. Are these 'new' viruses any more effective than their predecessors? What are the benefits of refining current clinical candidates compared to searching for new ones? This review briefly describes some of these novel oncolytic viruses. It also examines the issues that arise in comparing them to each other. We believe that the viral mechanism of action is a key factor to success and suggest guidelines by which all oncolytic virus candidates could be evaluated.
Collapse
Affiliation(s)
- Marianne M Stanford
- Centre for Cancer Therapeutics, Ottawa Health Research Institute, Ottawa, Ontario, Canada.
| | | | | |
Collapse
|
28
|
Evgin L, Vähä-Koskela M, Rintoul J, Falls T, Le Boeuf F, Barrett JW, Bell JC, Stanford MM. Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. Mol Ther 2010; 18:896-902. [PMID: 20160706 DOI: 10.1038/mt.2010.14] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
A number of oncolytic virus (OV) candidates currently in clinical trials are human viruses that have been engineered to be safer for patient administration by limiting normal cell targeting and replication. The newest OVs include viruses that cause no disease in humans, yet still have natural tumor tropism. Raccoonpox virus (RCNV) is a member of the Orthopoxvirus genus of Poxviridae and closely related to vaccinia virus, yet has no known pathogenicity in any mammalian species. A screen of cells from the NCI-60 cancer cell panel using growth curves demonstrated greater than a log increase in replication of RCNV in nearly 74% of the cell lines tested, similar to other tested OV poxviruses. In normal cell lines, pretreatment with interferon (IFN)-alpha/beta resulted in significant inhibition of RCNV replication. In both xenograft and syngeneic models of solid tumors, injection of RCNV resulted in significantly slower tumor progression and increased survival of mice. RCNV treatment also prolonged survival in treatment-resistant models of brain tumors and decreased tumor burden by systemic administration in models of lung metastasis.
Collapse
Affiliation(s)
- Laura Evgin
- Department of Biochemistry, University of Ottawa, Centre for Cancer Therapeutics, Ottawa Health Research Institute, Ottawa, Ontario, Canada
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Woo Y, Kelly KJ, Stanford MM, Galanis C, Chun YS, Fong Y, McFadden G. Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Ann Surg Oncol 2008; 15:2329-35. [PMID: 18454298 DOI: 10.1245/s10434-008-9924-z] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2007] [Revised: 03/24/2008] [Accepted: 03/25/2008] [Indexed: 02/06/2023]
Abstract
BACKGROUND Viral oncolytic therapy, which seeks to exploit the use of live viruses to treat cancer, has shown promise in the treatment of cancers resistant to conventional anticancer therapies. Among the most difficult to treat cancers is advanced pancreatic adenocarcinoma. Our study investigates the ability of a novel oncolytic agent, myxoma virus, to infect, productively replicate in, and kill human pancreatic cancer cells in vitro. METHODS The myxoma virus vMyxgfp was tested against a panel of human pancreatic adenocarcinoma cell lines. Infectivity, viral proliferation, and tumor cell kill were assessed. RESULTS Infection of tumor cells was assessed by expression of the marker gene enhanced green fluorescent protein (e-GFP). vMyxgfp had the ability to infect all pancreatic cancer cell lines tested. Killing of tumor cells varied among the 6 cell lines tested, ranging from >90% cell kill at 7 days for the most sensitive Panc-1 cells, to 39% in the most resistant cell line Capan-2. Sensitivity correlated to replication of virus, and was found to maximally exhibit a four-log increase in foci-forming units for the most sensitive Panc-1 cells within 72 h. CONCLUSION Our study demonstrates for the first time the ability of the myxoma virus to productively infect, replicate in, and lyse human pancreatic adenocarcinoma cells in vitro. These data encourage further investigation of this virus, which is pathogenic only in rabbits, for treatment of this nearly uniformly fatal cancer.
Collapse
Affiliation(s)
- Yanghee Woo
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
| | | | | | | | | | | | | |
Collapse
|
30
|
Barrett JW, Alston LR, Wang F, Stanford MM, Gilbert PA, Gao X, Jimenez J, Villeneuve D, Forsyth P, McFadden G. Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. J Neurovirol 2008; 13:549-60. [PMID: 18097886 DOI: 10.1080/13550280701591526] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
The authors have recently demonstrated that wild-type myxoma virus (MV) tagged with gfp (vMyxgfp) can generate a tumor-specific infection that productively infects and clears human tumor-derived xenografts when injected intratumorally into human gliomas transplanted into immunodeficient mice (Lun et al, 2005). To expand the understanding of MV tropism in cancer cells from a specific tissue lineage, the authors have screened a series of human glioma cells (U87, U118, U251, U343, U373) for myxoma virus replication and oncolysis. To assess the viral tropism determinants for these infections, the authors have screened myxoma virus knockout constructs that have been deleted for specific host range genes (M-T2, M-T4, M-T5, M11L, and M063), as well as a control MV gene knockout construct with no known host range function (vMyx135KO) but is highly attenuated in rabbits. The authors report wide variation in the ability of various vMyx-hrKOs to replicate and spread in the human glioma cells as measured by early and late viral gene expression. This differential ability to support vMyx-hrKO productive viral replication is consistent with levels of endogenous activated Akt in the various gliomas. The authors have identified one vMyx-hrKO virus (vMyx63KO) and one nonhost range knockout construct (vMyx135KO) that appear to replicate in the gliomas even more efficiently than the wild-type virus and that reduce the viability of the infected gliomas. These knockout viruses also inhibit the proliferation of gliomas in a manner similar to the wild-type virus. Together these data, as well as the fact that these knockout viruses are attenuated in their natural hosts, may represent environmentally safer candidate oncolytic viruses for usage in human trials.
Collapse
Affiliation(s)
- John W Barrett
- BioTherapeutics Research Group, Robarts Research Institute, and Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Stanford MM, Breitbach CJ, Bell JC, McFadden G. Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr Opin Mol Ther 2008; 10:32-37. [PMID: 18228179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
The field of oncolytic virus (OV) therapy is an innovative and evolving science, taking advantage of the ability of select viruses to preferentially infect and kill human tumor cells. However, the contribution of the tumor microenvironment, and especially the induced innate immune responses to both the tumor and the virus, has been demonstrated to be a major player in the success of OV therapies. Innate immunity and inflammation in particular can have opposing effects; these can augment OV therapy by enhancing tumor destruction, yet can also recognize and clear the invading virus to significantly hinder viral dissemination through the tumor tissues. This review considers how inflammation and innate immunity impinge on current OV candidates to either facilitate or hinder virotherapy. Novel approaches that modulate or harness the innate immune system to specifically enhance OV-mediated tumor destruction are also discussed.
Collapse
Affiliation(s)
- Marianne M Stanford
- Ottawa Health Research Institute, Centre for Cancer Therapeutics, Ottawa, Ontario, Canada
| | | | | | | |
Collapse
|
32
|
Lun XQ, Zhou H, Alain T, Sun B, Wang L, Barrett JW, Stanford MM, McFadden G, Bell J, Senger DL, Forsyth PA. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res 2007; 67:8818-27. [PMID: 17875723 PMCID: PMC4380180 DOI: 10.1158/0008-5472.can-07-1214] [Citation(s) in RCA: 86] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We have shown previously the oncolytic potential of myxoma virus in a murine xenograft model of human glioma. Here, we show that myxoma virus used alone or in combination with rapamycin is effective and safe when used in experimental models of medulloblastoma in vitro and in vivo. Nine of 10 medulloblastoma cell lines tested were susceptible to lethal myxoma virus infection, and pretreatment of cells with rapamycin increased the extent of in vitro oncolysis. Intratumoral injection of live myxoma virus when compared with control inactivated virus prolonged survival in D341 and Daoy orthotopic human medulloblastoma xenograft mouse models [D341 median survival: 21 versus 12.5 days; P = 0.0008; Daoy median survival: not reached (three of five mice apparently "cured" after 223 days) versus 75 days; P = 0.0021]. Rapamycin increased the extent of viral oncolysis, "curing" most Daoy tumor-bearing mice and reducing or eliminating spinal cord and ventricle metastases. Rapamycin enhanced tumor-specific myxoma virus replication in vivo and prolonged survival of D341 tumor-bearing mice (median survival of mice treated with live virus (LV) and rapamycin, versus LV alone, versus rapamycin alone, versus inactivated virus: 25 days versus 19, 13, and 11 days, respectively; P < 0.0001). Rapamycin increased the levels of constitutively activated Akt in Daoy and D341 cells, which may explain its ability to enhance myxoma virus oncolysis. These observations suggest that myxoma virus may be an effective oncolytic agent against medulloblastoma and that combination therapy with signaling inhibitors that modulate activity of the phosphatidylinositol 3-kinase/Akt pathway will further enhance the oncolytic potential of myxoma virus.
Collapse
Affiliation(s)
- Xue Qing Lun
- Departments of Oncology, Clinical Neurosciences, and Biochemistry and Molecular Biology and Tom Baker Cancer Centre, Calgary, Alberta, Canada
- Clark H. Smith Integrative Brain Tumour Research Centre, University of Calgary, Calgary, Alberta, Canada
| | - Hongyuan Zhou
- Departments of Oncology, Clinical Neurosciences, and Biochemistry and Molecular Biology and Tom Baker Cancer Centre, Calgary, Alberta, Canada
- Clark H. Smith Integrative Brain Tumour Research Centre, University of Calgary, Calgary, Alberta, Canada
| | - Tommy Alain
- Departments of Oncology, Clinical Neurosciences, and Biochemistry and Molecular Biology and Tom Baker Cancer Centre, Calgary, Alberta, Canada
- Clark H. Smith Integrative Brain Tumour Research Centre, University of Calgary, Calgary, Alberta, Canada
| | - Beichen Sun
- Departments of Oncology, Clinical Neurosciences, and Biochemistry and Molecular Biology and Tom Baker Cancer Centre, Calgary, Alberta, Canada
- Clark H. Smith Integrative Brain Tumour Research Centre, University of Calgary, Calgary, Alberta, Canada
| | - Limei Wang
- Departments of Oncology, Clinical Neurosciences, and Biochemistry and Molecular Biology and Tom Baker Cancer Centre, Calgary, Alberta, Canada
- Clark H. Smith Integrative Brain Tumour Research Centre, University of Calgary, Calgary, Alberta, Canada
| | - John W. Barrett
- BioTherapeutics Research Group, Robarts Research Institute and Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada
| | - Marianne M. Stanford
- BioTherapeutics Research Group, Robarts Research Institute and Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada
| | - Grant McFadden
- BioTherapeutics Research Group, Robarts Research Institute and Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada
- Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida
| | - John Bell
- Ottawa Regional Cancer Centre Research Laboratories, Ottawa, Ontario, Canada
| | - Donna L. Senger
- Departments of Oncology, Clinical Neurosciences, and Biochemistry and Molecular Biology and Tom Baker Cancer Centre, Calgary, Alberta, Canada
- Clark H. Smith Integrative Brain Tumour Research Centre, University of Calgary, Calgary, Alberta, Canada
| | - Peter A. Forsyth
- Departments of Oncology, Clinical Neurosciences, and Biochemistry and Molecular Biology and Tom Baker Cancer Centre, Calgary, Alberta, Canada
- Clark H. Smith Integrative Brain Tumour Research Centre, University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
33
|
Stanford MM, Shaban M, Barrett JW, Werden SJ, Gilbert PA, Bondy-Denomy J, Mackenzie L, Graham KC, Chambers AF, McFadden G. Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther 2007; 16:52-9. [PMID: 17998900 DOI: 10.1038/sj.mt.6300348] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Myxoma virus (MV) is a rabbit-specific poxvirus, whose unexpected tropism to human cancer cells has led to studies exploring its potential use in oncolytic therapy. MV infects a wide range of human cancer cells in vitro, in a manner intricately linked to the cellular activation of Akt kinase. MV has also been successfully used for treating human glioma xenografts in immunodeficient mice. This study examines the effectiveness of MV in treating primary and metastatic mouse tumors in immunocompetent C57BL6 mice. We have found that several mouse tumor cell lines, including B16 melanomas, are permissive to MV infection. B16F10 cells were used for assessing MV replication and efficacy in syngeneic primary tumor and metastatic models in vivo. Multiple intratumoral injections of MV resulted in dramatic inhibition of tumor growth. Systemic administration of MV in a lung metastasis model with B16F10LacZ cells was dramatically effective in reducing lung tumor burden. Combination therapy of MV with rapamycin reduced both size and number of lung metastases, and also reduced the induced antiviral neutralizing antibody titres, but did not affect tumor tropism. These results show MV to be a promising virotherapeutic agent in immunocompetent animal tumor models, with good efficacy in combination with rapamycin.
Collapse
Affiliation(s)
- Marianne M Stanford
- BioTherapeutics Research Group, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
Oncolytic virotherapy is an innovative alternative to more conventional cancer therapies. The ability of some viruses to specifically target and kill malignant cancerous cells while leaving normal tissue unscathed has opened a large repertoire of new and selective cancer killing therapeutic candidates. Poxviruses, such as vaccinia virus, have a long history of use in humans as live vaccines and have more recently been studied as potential platforms for delivery of immunotherapeutics and attenuated variants of vaccinia have been explored as oncolytic candidates. In contrast, the poxvirus myxoma virus is a novel oncolytic candidate that has no history of use in humans directly, as it has a distinct and absolute host species tropism to lagomorphs (rabbits). Myxoma virus has been recently shown to be able to also selectively infect and kill human tumor cells, a unique tropism that is linked to dysregulated intracellular signalling pathways found in the majority of human cancers. This review outlines the existing knowledge on the tropism of myxoma virus for human cancer cells, as well as preclinical data exhibiting its ability to infect and clear tumors in animal models of cancer. This is an exciting new therapeutic option for treating cancer, and myxoma virus joins a growing group of oncolytic virus candidates that are being developed as a new class of cancer therapies in man.
Collapse
Affiliation(s)
- Marianne M Stanford
- University of Western Ontario, Biotherapeutics Research Group, Robarts Research Institute, Department of Microbiology and Immunology, London, Ontario, N6G 2V4, Canada
| | | |
Collapse
|
35
|
Stanford MM, Barrett JW, Gilbert PA, Bankert R, McFadden G. Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbits. J Virol 2007; 81:12704-8. [PMID: 17728229 PMCID: PMC2168987 DOI: 10.1128/jvi.01483-07] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Myxoma virus (MV) is a candidate for oncolytic virotherapy due to its ability to selectively infect and kill tumor cells, yet MV is a species-specific pathogen that causes disease only in European rabbits. To assess the ability of MV to deliver cytokines to tumors, we created an MV (vMyxIL-12) that expresses human interleukin-12 (IL-12). vMyxIL-12 replicates similarly to wild-type MV, and virus-infected cells secrete bioactive IL-12. Yet, vMyxIL-12 does not cause myxomatosis, despite expressing the complete repertoire of MV proteins. Thus, vMyxIL-12 exhibits promise as an oncolytic candidate and is safe in all known vertebrate hosts, including lagomorphs.
Collapse
Affiliation(s)
- Marianne M Stanford
- Biotherapeutics Research Group, Robarts Research Institute, Department of Microbiology and Immunology, University of Western Ontario, London, ONT, Canada
| | | | | | | | | |
Collapse
|
36
|
Nazarian SH, Barrett JW, Stanford MM, Johnston JB, Essani K, McFadden G. Tropism of Tanapox virus infection in primary human cells. Virology 2007; 368:32-40. [PMID: 17632198 DOI: 10.1016/j.virol.2007.06.019] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2007] [Revised: 04/11/2007] [Accepted: 06/20/2007] [Indexed: 11/17/2022]
Abstract
Tanapox virus (TPV) belongs to the genus Yatapoxvirus and causes a relatively benign zoonotic disease in man, with symptoms that resemble a mild version of human monkeypox. In order to investigate the underlying mechanisms of TPV pathogenesis, the tropism and replication characteristics of TPV were examined in a variety of primary human cells. A GFP expressing TPV (TPV-GFP) was constructed and used to infect primary human dermal fibroblasts (pHDFs) and peripheral blood mononuclear cells (PBMCs), both of which are believed to be major in vivo targets of poxvirus infection. pHDFs fully supported productive replication and cell-cell spread of TPV-GFP. However, induction of cell cycle arrest in pHDFs by contact mediated inhibition or rapamycin treatment eliminated the ability of TPV to fully stimulate cell cycle progression and dramatically reduced viral replication. TPV-GFP-infected human PBMCs were screened for permissiveness by FACS analysis. CD14+ cells (monocytes) were the primary cellular target for TPV infection. A small proportion of CD3+ cells (T cells) were positive for GFP expression, yet TPV was not able to replicate and spread in cultured peripheral blood lymphocytes, regardless of their state of activation. Primary human monocytes, however, demonstrated robust TPV replication, yet these cells no longer supported replication of TPV once they differentiated into macrophages. This unique ex vivo tropism of TPV gives key insights into the basis for the self-limiting pathogenicity of TPV in man.
Collapse
Affiliation(s)
- Steven H Nazarian
- Biotherapeutics Research Group, Robarts Research Institute, Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada N6G 2V4
| | | | | | | | | | | |
Collapse
|
37
|
Stanford MM, Werden SJ, McFadden G. Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. Vet Res 2007; 38:299-318. [PMID: 17296158 DOI: 10.1051/vetres:2006054] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2006] [Accepted: 06/20/2006] [Indexed: 02/01/2023] Open
Abstract
Myxoma virus (MV) is a poxvirus that evolved in Sylvilagus lagomorphs, and is the causative agent of myxomatosis in European rabbits (Oryctolagus cuniculus). This virus is not a natural pathogen of O. cuniculus, yet is able to subvert the host rabbit immune system defenses and cause a highly lethal systemic infection. The interaction of MV proteins and the rabbit immune system has been an ideal model to help elucidate host/poxvirus interactions, and has led to a greater understanding of how other poxvirus pathogens are able to cause disease in their respective hosts. This review will examine how MV causes myxomatosis, by examining a selection of the identified immunomodulatory proteins that this virus expresses to subvert the immune and inflammatory pathways of infected rabbit hosts.
Collapse
Affiliation(s)
- Marianne M Stanford
- Biotherapeutics Research Group, Robarts Research Institute, University of Western Ontario, Siebens-Drake Building, Room 126, 1400 Western Road, London, Ontario, N6G 2V4, Canada
| | | | | |
Collapse
|
38
|
Abstract
Variola virus, the causative agent of smallpox, is a member of the poxvirus family and one of the most virulent human pathogens known. Although smallpox was eradicated almost 30 years ago, it is not understood why the mortality rates associated with the disease were high, why some patients recovered, and what constitutes an effective host response against infection. As variola virus infects only humans, our current understanding of poxvirus infections comes largely from historical clinical data from smallpox patients and from animal studies using closely related viruses such as ectromelia, myxoma and monkeypox. The outcome of an infection is determined by a complex interaction between the type of immune response mounted by the host and by evasion mechanisms that the virus has evolved to subvert it. Disease pathogenesis is also a function of both host and viral factors. Poxviruses are not only cytopathic, causing host tissue damage, but also encode an array of immunomodulatory molecules that affect the severity of disease. The ability of the host to control virus replication is therefore critical in limiting tissue damage. However, in addition to targeting virus, the immune response can inadvertently damage the host to such a degree that it causes illness and even death. There is growing evidence that many of the symptoms associated with serious poxvirus infections are a result of a 'cytokine storm' or sepsis and that this may be the underlying cause of pathology.
Collapse
|
39
|
Werden SJ, Barrett JW, Wang G, Stanford MM, McFadden G. M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A. J Virol 2006; 81:2340-8. [PMID: 17151107 PMCID: PMC1865929 DOI: 10.1128/jvi.01310-06] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The myxoma virus (MV) ankyrin repeat, host range factor M-T5 has the ability to bind and activate cellular Akt, leading to permissive MV replication in a variety of diverse human cancer cell lines (G. Wang, J. W. Barrett, M. Stanford, S. J. Werden, J. B. Johnston, X. Gao, M. Sun, J. Q. Cheng, and G. McFadden, Proc. Natl. Acad. Sci. USA 103:4640-4645, 2006). The susceptibility of permissive human cancer cells to MV infection is directly correlated with the basal or induced levels of phosphorylated Akt. When M-T5 is deleted from MV, the knockout virus, vMyxT5KO, can no longer productively infect a subset of human cancer cells (designated type II) that exhibit little or no endogenous phosphorylated Akt. In searching for a host counterpart of M-T5, we noted sequence similarity of M-T5 to a recently identified ankyrin repeat cellular binding protein of Akt called PIKE-A. PIKE-A binds and activates the kinase activity of Akt in a GTP-dependent manner and promotes the invasiveness of human cancer cell lines. Here, we demonstrate that transfected PIKE-A is able to rescue the ability of vMyxT5KO to productively infect type II human cancer cells that were previously resistant to infection. Also, cancer cells that were completely nonpermissive for both wild-type and vMyxT5KO infection (called type III) were rendered fully permissive following ectopic expression of PIKE-A. We conclude that the MV M-T5 host range protein is functionally interchangeable with the host PIKE-A protein and that the activation of host Akt by either M-T5 or PIKE-A is critical for the permissiveness of human cancer cells for MV.
Collapse
Affiliation(s)
- Steven J Werden
- Department of Microbiology and Immunology, University of Western Ontario and Robarts Research Institute, London, Ontario, Canada
| | | | | | | | | |
Collapse
|
40
|
Stanford MM, Barrett JW, Nazarian SH, Werden S, McFadden G. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol 2006; 81:1251-60. [PMID: 17108021 PMCID: PMC1797522 DOI: 10.1128/jvi.01408-06] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Myxoma virus is a rabbit-specific poxvirus pathogen that also exhibits a unique tropism for human tumor cells and is dramatically oncolytic for human cancer xenografts. Most tumor cell lines tested are permissive for myxoma infection in a fashion intimately tied to the activation state of Akt kinase. A host range factor of myxoma virus, M-T5, directly interacts with Akt and mediates myxoma virus tumor cell tropism. mTOR is a regulator of cell growth and metabolism downstream of Akt and is specifically inhibited by rapamycin. We report that treatment of nonpermissive human tumor cell lines, which normally restrict myxoma virus replication, with rapamycin dramatically increased virus tropism and spread in vitro. This increased myxoma replication is concomitant with global effects on mTOR signaling, specifically, an increase in Akt kinase. In contrast to the effects on human cancer cells, rapamycin does not increase myxoma virus replication in rabbit cell lines or permissive human tumor cell lines with constitutively active Akt. This indicates that rapamycin increases the oncolytic capacity of myxoma virus for human cancer cells by reconfiguring the internal cell signaling environment to one that is optimal for productive virus replication and suggests the possibility of a potentially therapeutic synergism between kinase signaling inhibitors and oncolytic poxviruses for cancer treatment.
Collapse
Affiliation(s)
- Marianne M Stanford
- Biotherapeutics Research Group, Robarts Research Institute, Department of Microbiology and Immunology, University of Western Ontario, London, Ontario N6G 2V4, Canada
| | | | | | | | | |
Collapse
|
41
|
Stanford MM, McFadden G. The ‘supervirus’? Lessons from IL-4-expressing poxviruses. Trends Immunol 2005; 26:339-45. [PMID: 15922951 DOI: 10.1016/j.it.2005.04.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2005] [Revised: 03/09/2005] [Accepted: 04/05/2005] [Indexed: 01/26/2023]
Abstract
Members of the Poxviridae family are particularly adept at avoiding the host immune system, encoding a plethora of immunomodulatory proteins that subvert host defense. With their large genome, poxviruses are also useful for studying the effect of exogenous genes on virus-host interactions and immune responses. The insertion of the Th2 cytokine interleukin-4 (IL-4) into several poxviruses significantly increases the efficiency of the recombinant virus as a pathogen by directly inhibiting the development of Th1 immunity, which is crucial for viral clearance. In an age in which the fear of genetically modified weaponized pathogens exists, the understanding of how to make viruses more pathogenic further blurs the distinction between fundamental academic research and bioweapons development. Here, the extent of immune evasion by IL-4-expressing poxviruses will be explored, as will the consequences of this increased pathogenicity on protective immune responses.
Collapse
Affiliation(s)
- Marianne M Stanford
- BioTherapeutics Research Group, Robarts Research Institute & Microbiology and Immunology, University of Western Ontario, London, Ontario N6G 2V4, Canada
| | | |
Collapse
|
42
|
Stanford MM, Issekutz TB. The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo. J Leukoc Biol 2003; 74:791-9. [PMID: 12960247 DOI: 10.1189/jlb.1102547] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
In chronic inflammatory reactions such as rheumatoid arthritis and multiple sclerosis, T cells in the inflamed tissue express the chemokine receptors CXCR3 and CCR5, and the chemokine ligands (CCL) of these receptors are present in the inflammatory lesions. However, the contribution of these chemokines to T cell recruitment to sites of inflammation is unclear. In addition, the relative roles of the chemokines that bind CXCR3 (CXCL9, CXCL10, CXCL11) and CCR5 (CCL3, CCL4, CCL5) in this process are unknown. The in vitro chemotaxis and in vivo migration of antigen-activated T lymphoblasts and unactivated spleen T cells to chemokines were examined. T lymphoblasts migrated in vitro to CXCR3 ligands with a relative potency of CXCL10 > CXCL11 > CXCL9, but these cells demonstrated much less chemotaxis to the CCR5 ligands. In vivo, T lymphocytes were recruited in large numbers with rapid kinetics to skin sites injected with CXCL10 and CCL5 and less to CCL3, CCL4, CXCL9, and CXCL11. The combination of CCL5 with CXCL10 but not the other chemokines markedly increased recruitment. Coinjection of interferon-gamma, tumor necrosis factor alpha, and interleukin-1alpha to up-regulate endothelial cell adhesion molecule expression with CXCL10 or CCL5 induced an additive increase in lymphoblast migration. Thus, CXCR3 ligands are more chemotactic than CCR5 ligands in vitro; however, in vivo, CXCL10 and CCL5 have comparable T cell-recruiting activities to cutaneous sites and are more potent than the other CXCR3 and CCR5 chemokines. Therefore, in vitro chemotaxis induced by these chemokines is not necessarily predictive of their in vivo lymphocyte-recruiting activity.
Collapse
Affiliation(s)
- Marianne M Stanford
- Departments of Microbiology & Immunology, Dalhousie University Avenue, Halifax, Nova Scotia, Canada
| | | |
Collapse
|
43
|
Verginis P, Stanford MM, Carayanniotis G. Delineation of five thyroglobulin T cell epitopes with pathogenic potential in experimental autoimmune thyroiditis. J Immunol 2002; 169:5332-7. [PMID: 12391254 DOI: 10.4049/jimmunol.169.9.5332] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Experimental autoimmune thyroiditis (EAT) is a T cell-mediated disease that can be induced in mice after challenge with thyroglobulin (Tg) or Tg peptides. To date, five pathogenic Tg peptides have been identified, four of which are clustered toward the C-terminal end. Because susceptibility to EAT is under control of H-2A(k) genes, we have used an algorithm-based approach to identify A(k)-binding peptides with pathogenic potential within mouse Tg. Eight candidate synthetic peptides, varying in size from 9 to 15 aa, were tested and five of those (p306, p1579, p1826, p2102, and p2596) were found to induce EAT in CBA/J (H-2(k)) mice either after direct challenge with peptide in adjuvant or by adoptive transfer of peptide-sensitized lymph node cells (LNCs) into naive hosts. These pathogenic peptides were immunogenic at the T cell level, eliciting specific LNC proliferative responses and IL-2 and/or IFN-gamma secretion in recall assays in vitro, but contained nondominant epitopes. All immunogenic peptides were confirmed as A(k) binders because peptide-specific LNC proliferation was blocked by an A(k)-specific mAb, but not by a control mAb. Peptide-specific serum IgG was induced only by p2102 and p2596, but these Abs did not bind to intact mouse Tg. This study reaffirms the predictive value of A(k)-binding motifs in epitope mapping and doubles the number of known pathogenic T cell determinants in Tg that are now found scattered throughout the length of this large autoantigen. This knowledge may contribute toward our understanding of the pathogenesis of autoimmune thyroiditis.
Collapse
Affiliation(s)
- Panayotis Verginis
- Division of Endocrinology, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Canada
| | | | | |
Collapse
|